# GPT-only vs RAG Benchmark

Generated: 2026-06-04T15:51:07

Questions file: `data/eval_en_questions.txt`

No automatic correctness scoring is applied.

## Summary

- Total questions: 52
- HIGH retrieval strength: 27
- MEDIUM retrieval strength: 25
- LOW retrieval strength: 0
- HIGH evidence diversity: 25
- MEDIUM evidence diversity: 9
- LOW evidence diversity: 18

## Results

## Q1: How does ER stress induce paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Mechanism
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4076
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does ER stress induce paraptosis?

### GPT answer

ER stress can induce **paraptosis**, a caspase-independent form of programmed cell death, mainly by overwhelming the ER’s protein-folding and calcium-handling capacity.

Mechanistically:

1. **Misfolded protein accumulation**
   - ER stress causes unfolded/misfolded proteins to build up.
   - If the unfolded protein response cannot restore homeostasis, ER proteostasis fails.

2. **Sustained UPR signaling**
   - Chronic activation of **PERK–eIF2α–ATF4–CHOP**, **IRE1–JNK**, and related stress pathways shifts the cell from adaptation to death.
   - Unlike apoptosis, this does not primarily depend on caspase activation.

3. **ER swelling and vacuolization**
   - Paraptosis is characterized by extensive cytoplasmic vacuoles derived largely from swollen **ER** and sometimes mitochondria.
   - Continued protein synthesis and ER osmotic/structural stress contribute to ER dilation.

4. **Calcium dysregulation**
   - ER stress disrupts ER Ca²⁺ storage.
   - Ca²⁺ release into the cytosol and uptake by mitochondria promote mitochondrial dysfunction.

5. **ROS and mitochondrial damage**
   - Mitochondrial Ca²⁺ overload and ER–mitochondrial stress increase **reactive oxygen species**.
   - ROS further damages ER and mitochondrial membranes, amplifying vacuolization.

6. **MAPK pathway activation**
   - Paraptosis often involves sustained activation of **MAPK signaling**, especially **ERK**, **JNK**, and/or **p38**, depending on the stimulus.
   - These pathways promote cytoplasmic vacuolation and non-apoptotic death.

7. **Proteasome/ERAD overload**
   - If ER-associated degradation is impaired or overwhelmed, misfolded proteins accumulate further.
   - This favors persistent ER stress and paraptotic morphology.

In short, **ER stress induces paraptosis by overwhelming ER proteostasis, disrupting Ca²⁺ balance, activating stress MAPK signaling, generating ROS, and causing massive ER/mitochondrial swelling with cytoplasmic vacuolization**, usually without caspase activation or classic apoptotic morphology.

### RAG answer

ER stress induces paraptosis primarily by overwhelming ER proteostasis, activating the UPR, and driving ER–mitochondrial Ca²⁺ dysregulation that produces the hallmark phenotype of ER/mitochondrial dilation and cytoplasmic vacuolization.
Mechanistically, newly synthesized or misfolded proteins accumulate in the ER—often after proteasome inhibition, impaired chaperone function, or chemical disruption of protein folding. This activates ER stress and the unfolded protein response through BiP dissociation from PERK, IRE1α, and ATF6; if stress is prolonged or exceeds adaptive capacity, the response shifts from homeostatic rescue toward cell death [PMC11533606:sec7:chunk0; PMC12985128:sec2:chunk1]. Paraptosis appears to require ongoing transcription and translation, consistent with the idea that continued protein synthesis feeds the proteotoxic ER burden [PMC11606808:sec2:chunk0].
The direct morphological link is osmotic: accumulation of misfolded proteins within the ER lumen is thought to generate osmotic pressure, drawing water into the ER and causing ER dilation, one of the defining features of paraptosis [PMC7873879:abstract:chunk0; PMC11420017:sec17:chunk0]. Proteasomal inhibition or sulfhydryl/protein-folding disruption can therefore promote paraptosis by increasing ubiquitinated or misfolded protein load and ER stress markers such as BiP and CHOP [PMC10308048:sec17:chunk1].
ER stress also perturbs Ca²⁺ homeostasis. Ca²⁺ release from the stressed/dilated ER can aggravate ER stress and, through ER–mitochondrial contact sites, drive mitochondrial Ca²⁺ overload; this contributes to mitochondrial swelling/dilation during paraptosis [PMC7873879:abstract:chunk0; PMC11420017:sec17:chunk0]. Thus, the sequence is: proteotoxic ER burden → UPR activation → ER dilation/vacuolization plus ER-to-mitochondria Ca²⁺ flux → mitochondrial dilation → paraptotic cell death.
UPR components are not merely markers in several models: ATF4 knockdown reduced curcuminoid B63-induced paraptosis, ATF4 or CHOP knockout delayed vinigrol-induced paraptosis, CHOP knockdown attenuated dimethoxycurcumin-induced ER dilation and death, and pharmacologic inhibition of the PERK–eIF2α axis impaired osimertinib-induced paraptosis [PMC11533606:sec7:chunk1]. However, CHOP alone should not be treated as a definitive paraptosis-specific switch; the retrieved evidence supports a coordinated ER proteostasis/UPR/Ca²⁺ mechanism rather than a single universal trigger [PMC10308048:sec17:chunk1].

---

## Q2: What role does calcium homeostasis play in paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Mechanism
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4578
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What role does calcium homeostasis play in paraptosis?

### GPT answer

Calcium homeostasis is a key regulator of paraptosis, mainly through disruption of ER–mitochondria signaling.

In paraptosis, impaired Ca²⁺ handling can cause:

- **ER Ca²⁺ depletion**, leading to **ER stress**, unfolded protein response activation, and ER swelling.
- **Excess cytosolic Ca²⁺**, which perturbs ion balance and promotes cellular stress.
- **Mitochondrial Ca²⁺ overload**, causing mitochondrial dysfunction, loss of membrane potential, ATP depletion, and increased ROS production.
- **ER and mitochondrial dilation/vacuolization**, a hallmark morphology of paraptosis.
- Activation of stress pathways such as **MAPK/JNK/ERK signaling**, which can reinforce paraptotic death.

Mechanistically, paraptosis often arises when Ca²⁺ transfer between the ER and mitochondria becomes excessive or poorly controlled. This promotes organelle swelling and proteotoxic/oxidative stress rather than caspase-dependent apoptosis.

So, calcium homeostasis acts as a central stress-control system in paraptosis: when Ca²⁺ storage, release, or uptake is disrupted, it can drive the ER/mitochondrial dysfunction and vacuolization characteristic of paraptotic cell death.

### RAG answer

Calcium homeostasis is a central regulator of paraptosis because its disruption links ER stress, organelle swelling, and ER–mitochondrial communication—the core morphological features of paraptotic death. Paraptosis is characterized by cytoplasmic vacuolation due to dilation of the ER and/or mitochondria, and imbalanced ion homeostasis, particularly Ca²⁺, is one of the proposed upstream triggers of this process [PMC7873879:sec0:chunk0].
Mechanistically, depletion or redistribution of ER Ca²⁺ impairs ER protein-folding capacity, because multiple ER chaperones and folding enzymes—including BiP/GRP78, PDI, GRP94, and ERp57/PDIA3—depend on Ca²⁺ binding for proper function. Activation of ER Ca²⁺-release channels such as IP3 receptors or ryanodine receptors can therefore promote ER stress, misfolded protein accumulation, osmotic water influx, and ER dilation, producing the vacuolated phenotype typical of paraptosis [PMC7873879:sec18:chunk0; PMC11533606:sec8:chunk0].
Calcium also drives the mitochondrial component of paraptosis through ER–mitochondrial Ca²⁺ flux. Ca²⁺ released from the ER can be transferred to mitochondria through the ER–mitochondrial axis, involving channels such as VDACs and mitochondrial Ca²⁺ uniporters; excessive mitochondrial Ca²⁺ loading increases osmotic stress, ROS generation in some settings, and mitochondrial swelling [PMC7873879:abstract:chunk0; PMC11533606:sec8:chunk0]. Thus, ER Ca²⁺ loss and mitochondrial Ca²⁺ overload form a coupled mechanism: ER stress and dilation on one side, mitochondrial dilation on the other.
The available evidence also indicates that several paraptosis-inducing agents act by perturbing Ca²⁺ transport rather than by engaging classical apoptosis. Natural products, metal complexes, proteasome inhibitors combined with Ca²⁺-modulating agents, and compounds affecting IP3R/RyR-, VDAC-, MCU-, or mNCX-linked Ca²⁺ handling have all been associated with paraptotic responses [PMC7873879:abstract:chunk0; PMC10308048:sec20:chunk0; PMC11533606:sec8:chunk0]. In this sense, Ca²⁺ homeostasis is not merely a bystander change but a mechanistic bridge between proteostasis failure, osmotic organelle dilation, and caspase-independent paraptotic cell death.

---

## Q3: How do reactive oxygen species (ROS) contribute to paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Mechanism
- Retrieval strength: MEDIUM
- Evidence diversity: MEDIUM
- Top1 score: 0.6400
- Top5 avg score: 0.4763
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How do reactive oxygen species (ROS) contribute to paraptosis?

### GPT answer

Reactive oxygen species (ROS) can drive or amplify **paraptosis**, a non-apoptotic form of cell death characterized by extensive cytoplasmic vacuolization, especially from the **endoplasmic reticulum (ER)** and mitochondria.

Mechanistically, ROS contribute to paraptosis by:

- **Inducing ER stress:** ROS oxidize proteins and disturb ER redox balance, causing misfolded protein accumulation and activation of the unfolded protein response.
- **Disrupting Ca²⁺ homeostasis:** Oxidative stress can alter ER and mitochondrial calcium handling, promoting organelle swelling and vacuole formation.
- **Damaging mitochondria:** ROS impair mitochondrial function, increasing mitochondrial swelling and further ROS production.
- **Inhibiting proteostasis:** ROS can impair proteasome function, leading to accumulation of unfolded or damaged proteins, which promotes ER dilation.
- **Activating stress signaling pathways:** ROS can activate MAPK pathways such as **JNK, p38, and ERK**, which are often involved in paraptotic cell death.
- **Creating a feed-forward loop:** Mitochondrial dysfunction generates more ROS, which further worsens ER stress and organelle damage.

Unlike apoptosis, ROS-driven paraptosis typically occurs without prominent caspase activation, DNA fragmentation, or apoptotic body formation. Antioxidants often reduce paraptotic vacuolization and cell death, supporting ROS as an important mediator.

### RAG answer

ROS contribute to paraptosis both as stress-derived byproducts and as active signaling amplifiers that drive the paraptotic phenotype—ER/mitochondrial swelling, extensive cytoplasmic vacuolization, proteotoxic stress, and caspase-independent cell death [PMC12564638:sec16:chunk0].
Mechanistically, ROS commonly arise from mitochondrial dysfunction, proteasome inhibition, and redox-system imbalance. During paraptosis, damaged mitochondria show altered membrane potential, impaired oxidative phosphorylation, and increased electron leakage from the electron transport chain, which promotes ROS overproduction [PMC11533606:sec9:chunk0; PMC10308048:sec18:chunk0]. Disruption of antioxidant buffering systems, including thioredoxin and glutathione pathways, further shifts cells toward oxidative stress [PMC11533606:sec9:chunk0; PMC10308048:sec18:chunk0].
ROS then reinforce paraptosis by coupling mitochondrial injury to ER stress and MAPK signaling. Excess ROS can increase mitochondrial Ca²⁺ levels, activate pathways such as ERK/MAPK, and promote vacuolization; examples in the retrieved evidence include ROS-mediated mitochondrial Ca²⁺ elevation leading to ERK activation and vacuolization in HepG2 cells, and δ-tocotrienol-induced Ca²⁺ overload/ROS followed by MAPK activation in melanoma cells [PMC11533606:sec9:chunk0; PMC11533606:sec9:chunk1]. More broadly, paraptosis often requires sustained MAPK activation, particularly ERK and JNK, together with ER stress and protein-homeostasis disruption [PMC12564638:sec16:chunk0].
A key feature is positive feedback: elevated mitochondrial ROS can impair proteasome activity, while proteasome dysfunction further enhances mitochondrial electron leakage and ROS production. This can stabilize Ca²⁺-handling components such as IP3R and MCU, intensifying Ca²⁺-dependent ER stress, vacuolization, and eventual paraptotic death [PMC11533606:sec9:chunk1]. Thus, ROS are not simply markers of paraptosis; they help initiate and amplify the mitochondrial–ER stress–proteostasis loop that executes the process [PMC11533606:sec4:chunk0; PMC12564638:sec16:chunk0].

---

## Q4: How does MAPK/ERK signaling participate in paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Mechanism
- Retrieval strength: HIGH
- Evidence diversity: HIGH
- Top1 score: 0.9171
- Top5 avg score: 0.5977
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does MAPK/ERK signaling participate in paraptosis?

### GPT answer

MAPK/ERK signaling participates in paraptosis mainly as a **pro-death, sustained stress-signaling pathway**, not as the transient growth/survival ERK signal seen after mitogenic stimulation.

Mechanistically, sustained MEK–ERK activation can promote paraptosis by:

- **Driving cytoplasmic vacuolization**, especially dilation of the **endoplasmic reticulum and mitochondria**, a hallmark of paraptosis.
- **Amplifying ER stress and unfolded-protein stress**, often linked to impaired protein handling/proteasome function.
- **Promoting ROS production and mitochondrial dysfunction**, which can further sustain ERK activation in a feed-forward loop.
- **Disturbing Ca²⁺ homeostasis**, contributing to ER and mitochondrial swelling.
- Supporting **caspase-independent cell death**, since paraptosis generally lacks classic apoptotic caspase activation, chromatin condensation, and apoptotic bodies.

Experimentally, inhibition of MEK/ERK often reduces vacuole formation and paraptotic cell death, suggesting ERK activity is functionally required in many models. However, this is **context-dependent**: ERK can be protective or lethal depending on stimulus intensity, duration, and cell type.

### RAG answer

MAPK/ERK signaling participates as a pro-paraptotic signaling axis that links upstream stress or receptor activation to proteotoxic ER stress, ER/mitochondrial vacuolization, and ultimately non-apoptotic cell death. Paraptosis is described as caspase-independent and characterized by cytoplasmic vacuolization, with MAPK signaling being a major mediator rather than an apoptotic caspase pathway [PMC11163730:sec0:chunk0].
Mechanistically, activation of MEK1/2–ERK1/2 promotes nascent protein synthesis—shown, for example, by increased MEK/ERK phosphorylation and downstream eIF4E phosphorylation—which can increase misfolded protein burden, provoke ER stress/UPR signaling, and drive paraptotic morphology such as ER dilation and cytoplasmic vacuoles [PMC12056802:sec12:chunk0; PMC9468165:sec3:chunk0]. In IL-1β-treated chondrocytes, MEK/ERK activation coincided with increased p-PERK and CHOP, and MEK inhibition reduced ER dilation, vacuolization, ER-stress markers, and cell viability loss [PMC12056802:sec12:chunk0]. Similarly, in elaiophylin-treated ovarian cancer cells, MEK/ERK activation increased eIF4E phosphorylation and CHOP, while U0126 or MEK/ERK knockdown suppressed vacuolization, ER stress, and cell death [PMC9468165:sec3:chunk0].
MAPK/ERK can be engaged by multiple paraptotic triggers. IGF1R-induced paraptosis was linked to downstream MAPK/ERK and JNK pathways, and inhibition of MEK-2 or JNK-1 suppressed this response; AIP-1/Alix functions as an endogenous inhibitor by counteracting MAPK-dependent paraptosis [PMC11546839:sec12:chunk0]. Other contexts include SHP2/MAPK-driven paraptosis, ROS-enhanced MAPK activation after TrxR1 inhibition/GSH depletion, and GPCR–Ca²⁺–PKCα signaling that activates ERK/JNK/p38 MAPKs during paraptotic induction [PMC11533606:sec10:chunk0].
The contribution of ERK is context-dependent but repeatedly functional: MEK/ERK blockade diminishes hallmark vacuolization and ER stress in several models, whereas in swainsonine-treated renal tubular epithelial cells ERK and JNK inhibition reduced vacuolization without markedly reducing cell death [PMC8383073:sec12:chunk0]. Thus, MAPK/ERK is best viewed as a central amplifier/mediator of the paraptotic program—especially through protein-synthesis-driven ER proteotoxic stress—rather than a universally sufficient determinant of cell death in every paraptosis model.

---

## Q5: What is the role of JNK activation in paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Mechanism
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.5060
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What is the role of JNK activation in paraptosis?

### GPT answer

JNK activation in paraptosis generally acts as a **pro-death signaling event**, often linking cellular stress to the characteristic **cytoplasmic vacuolization** and caspase-independent death.

Mechanistically, sustained JNK activation can:

- Promote or amplify **ER stress** and unfolded protein stress.
- Enhance **ROS production** and mitochondrial dysfunction.
- Support formation of large **ER/mitochondria-derived vacuoles**, a hallmark of paraptosis.
- Drive death independently of caspase activation, distinguishing it from classical apoptosis.

In many experimental systems, pharmacologic or genetic inhibition of JNK reduces vacuolization and cell death, suggesting JNK is functionally required or contributory. However, its role is **context-dependent**: JNK activation is not an obligatory universal marker of paraptosis, but when sustained, it often helps execute or amplify the paraptotic program.

### RAG answer

JNK activation can function as a pro-paraptotic MAPK signal that links cellular stress—especially ROS and ER stress—to the vacuolated, caspase-independent death phenotype of paraptosis, but its requirement is stimulus- and cell-context-dependent.
Mechanistically, paraptosis is generally distinguished from apoptosis by cytoplasmic vacuolization, ER/mitochondrial dilation, and relative independence from classical caspase-dependent apoptotic execution; MAPK signaling, including JNK, is repeatedly implicated as part of its regulatory framework [PMC11546839:abstract:chunk0]. In the canonical IGF-IR model, IGF-IR-induced paraptosis depends on downstream MAPK/JNK signaling, because MEK-2 inhibition and antisense targeting of JNK-1 suppress the paraptotic response in 293T cells [PMC11546839:sec12:chunk0].
In stress-induced paraptosis, JNK appears to act downstream of organellar stress. For example, photodynamic ER/mitochondrial damage activates ER-stress pathways—IRE1α/XBP1 and PERK-associated BiP/CHOP signaling—followed by JNK activation; pharmacologic JNK inhibition prevented paraptotic cell death, whereas p38 inhibition did not block paraptosis in that model [PMC7998908:sec13:chunk0]. Similarly, in non-small cell lung cancer, mitocurcumin increased JNK phosphorylation in a ROS-dependent manner, and either ROS scavenging or JNK inhibition reversed paraptosis markers, supporting a ROS → JNK → paraptosis axis [PMC13086902:sec12:chunk0].
However, JNK activation is not universally required for all paraptotic programs. In cetylpyridinium chloride–treated pancreatic cancer cells, both p38 and JNK phosphorylation increased, but JNK inhibition failed to block cytotoxicity, whereas MAP3K5 or p38 inhibition reduced cytotoxicity, vacuolization, and ER dilation; this supports an ERN1–MAP3K5–p38-driven paraptosis pathway in which JNK activation is present but dispensable [PMC11357866:sec6:chunk0].
Thus, JNK’s role in paraptosis is best viewed as a stress-activated pro-death MAPK module that can be necessary in ROS/ER-stress- or IGF-IR-associated paraptosis, rather than a universal executioner of paraptosis across all stimuli.

---

## Q6: What is the role of PI4KB in paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Molecular regulators
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 1.0000
- Top5 avg score: 0.5712
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What is the role of PI4KB in paraptosis?

### GPT answer

PI4KB appears to act as a **positive mediator of paraptosis** in reported models, rather than as a general apoptosis-like executioner.

Mechanistically, PI4KB is a Golgi/ER-associated lipid kinase that produces **PI4P**, a phosphoinositide needed for membrane trafficking and organelle homeostasis. During paraptosis, PI4KB activity can contribute to:

- **ER/Golgi membrane dysregulation**
- **cytoplasmic vacuolization**, a hallmark of paraptosis
- **ER stress and organelle swelling**
- **caspase-independent cell death**

Accordingly, PI4KB inhibition or knockdown has been reported to reduce paraptotic vacuole formation and cell death in some systems.

So, PI4KB’s role is best described as an **upstream membrane-lipid signaling regulator that promotes the organelle swelling/vacuolization characteristic of paraptosis**.

### RAG answer

Evidence insufficient to define PI4KB as a direct mechanistic effector or inducer of paraptosis. The retrieved study identifies PI4KB as a **paraptosis-related breast cancer biomarker** rather than demonstrating that PI4KB itself triggers paraptotic cell death.
Mechanistically, PI4KB was prioritized because it showed oncogenic/prognostic relevance and was **bioinformatically linked to the ER stress–AKT/MAPK axis**, a pathway context relevant to paraptosis; however, the authors explicitly note that PI4KB’s role in paraptosis had been “unexplored” before their validation work [PMC12685561:sec24:chunk0]. This matters because paraptosis is described as caspase-independent cell death characterized by ER/mitochondrial vacuolization and involving processes such as ER stress, calcium imbalance, protein aggregation, and MAPK signaling [PMC12685561:sec0:chunk0].
In breast cancer, PI4KB appears to function more clearly as an **oncogenic, paraptosis-associated marker**: it was included among six genes used to build a paraptosis-related risk score, showed relatively high copy-number amplification, was highly expressed in breast cancer, and its knockdown suppressed breast cancer cell proliferation, colony formation, migration, and invasion [PMC12685561:sec18:chunk0; PMC12685561:sec24:chunk0; PMC12685561:abstract:chunk0]. The study concludes that PI4KB may be a prognostic biomarker and therapeutic target in breast cancer within a paraptosis-related gene framework [PMC12685561:sec26:chunk0].
So, the best supported interpretation is: **PI4KB is associated with paraptosis-related transcriptional/prognostic programs in breast cancer and promotes malignant phenotypes, but its direct causal role in paraptotic cell death remains unproven in the retrieved evidence**.

---

## Q7: How does proteasome inhibition trigger paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Molecular regulators
- Retrieval strength: HIGH
- Evidence diversity: MEDIUM
- Top1 score: 0.8636
- Top5 avg score: 0.5913
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does proteasome inhibition trigger paraptosis?

### GPT answer

Proteasome inhibition can trigger **paraptosis** by creating severe, unresolved **proteotoxic and ER stress** rather than by activating the caspase apoptotic machinery.

Mechanistically:

1. **Blocked protein degradation**  
   Proteasome inhibitors prevent clearance of ubiquitinated, misfolded, and short-lived regulatory proteins.

2. **ER-associated degradation fails**  
   Misfolded proteins accumulate in the ER/cytosol, overwhelming chaperones and activating a sustained **unfolded protein response**.

3. **ER swelling and vacuolization**  
   Persistent protein accumulation and osmotic/ionic imbalance cause dilation of ER cisternae, producing the large cytoplasmic vacuoles typical of paraptosis.

4. **Ca²⁺ and ROS dysregulation**  
   ER stress can disturb Ca²⁺ homeostasis, promote mitochondrial stress, increase ROS, and cause mitochondrial swelling.

5. **Stress kinase amplification**  
   Pathways such as **MAPK signaling**—often ERK, JNK, or p38 depending on cell type—can reinforce the paraptotic program.

6. **Caspase-independent death**  
   Unlike apoptosis, paraptosis usually lacks nuclear fragmentation, apoptotic bodies, and caspase dependence; caspase inhibitors generally do not block it.

In short: **proteasome inhibition causes toxic buildup of undegraded proteins, overwhelming ER quality-control systems, leading to ER/mitochondrial swelling, vacuolization, stress signaling, and caspase-independent paraptotic death.**

### RAG answer

Proteasome inhibition can trigger paraptosis by converting proteotoxic stress into a self-amplifying ER–mitochondria stress program: blocked proteasomal degradation causes accumulation of ubiquitinated/misfolded proteins, overloads ER protein quality control, activates UPR/ER stress, and—when unresolved—drives cytoplasmic vacuolization with ER and mitochondrial swelling rather than caspase-dependent apoptosis [PMC11533606:sec6:chunk0; PMC11533606:sec3:chunk0; PMC12221825:sec0:chunk0].
Mechanistically, the inhibited proteasome prevents normal clearance of ubiquitin-tagged and misfolded proteins, including proteins normally routed through ER-associated degradation. Their accumulation in the ER activates UPR signaling and stress-response transcription/translation; this fits the defining feature that paraptosis is dependent on new RNA/protein synthesis, since transcription or translation inhibitors can reduce vacuolization [PMC10308048:sec17:chunk0; PMC11533606:sec3:chunk0]. UPR markers such as p-eIF2α, ATF4, and CHOP are reported to rise after PSMD14 targeting/proteasome inhibition in breast cancer cells, linking proteasome blockade to ER-stress signaling in a paraptotic context [PMC8910635:sec2:chunk0].
The ER stress then engages mitochondria through ER–mitochondria coupling and Ca²⁺/redox imbalance. Proteasome disruption is associated with mitochondrial dysfunction, loss of membrane potential, impaired ATP and Ca²⁺ homeostasis, increased electron leakage, and ROS generation [PMC11533606:sec6:chunk1]. ROS can further impair proteasome activity, while proteasome impairment can intensify ER stress, UPR activation, mitochondrial dysfunction, and vacuole formation—creating a positive feedback loop that amplifies paraptotic death signaling [PMC11533606:sec9:chunk1; PMC11533606:sec17:chunk0].
Importantly, the retrieved evidence suggests proteasome inhibition is a major trigger but not always sufficient by itself. In one PSMD14-targeting study, bortezomib produced stronger proteasome inhibition and more ubiquitinated protein accumulation than the paraptosis-inducing PSMD14 inhibitor, yet caused cytostasis without the characteristic morphological change in the same cell line [PMC8910635:sec2:chunk0]. Thus, proteasome inhibition appears to promote paraptosis most effectively when coupled to unresolved ER stress, de novo protein synthesis, Ca²⁺/ROS dysregulation, and ER–mitochondrial vacuolation.

---

## Q8: What is the function of Alix (AIP1) in regulating paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Molecular regulators
- Retrieval strength: HIGH
- Evidence diversity: HIGH
- Top1 score: 1.0000
- Top5 avg score: 0.5938
- Coverage: 0.7500
- Evidence count: 8
- Normalized retrieval query: What is the function of Alix (AIP1) in regulating paraptosis?

### GPT answer

Alix (AIP1/PDCD6IP) functions mainly as a **negative regulator of paraptosis**.

Mechanistically, Alix helps restrain the paraptotic program characterized by **extensive cytoplasmic vacuolization**, organelle swelling, and caspase-independent death. When Alix is overexpressed, it can suppress paraptosis-like cell death; when Alix is reduced or absent, cells become more susceptible to paraptotic vacuolation and death.

Its protective role is thought to involve its membrane-remodeling/endosomal functions, including ESCRT-associated trafficking, and possibly modulation of stress signaling pathways linked to paraptosis. Thus, Alix acts as an anti-paraptotic factor rather than an executor of paraptosis.

### RAG answer

Alix/AIP1 functions primarily as an endogenous inhibitor of paraptosis. In IGF-IR/IGF1R-driven paraptotic signaling, Alix counteracts the pathway by attenuating downstream MAPK and JNK activity, thereby blocking paraptosis induction rather than broadly suppressing apoptosis [PMC11546839:sec12:chunk0; PMC12985128:sec10:chunk0].
Mechanistically, the pathway can be framed as: IGF-IR activation → MAPK/JNK signaling → paraptotic cytoplasmic vacuolization; Alix interrupts this signaling axis, limiting the paraptotic phenotype [PMC11546839:sec12:chunk0; PMC10308048:sec15:chunk0]. This inhibitory role is consistent with reports that paraptosis-inducing treatments are associated with reduced Alix/AIP1 expression, including EKB-induced paraptosis in lung cancer cells and YRL1091-induced paraptosis in breast cancer cells [PMC10308048:sec30:chunk0; PMC8773266:sec15:chunk0].
Alix downregulation is therefore often used as supportive evidence of paraptotic cell death, while Alix overexpression can attenuate paraptosis; in the retrieved evidence, this rescue is linked to suppression of ROS-associated paraptotic responses in cancer cells [PMC11533606:sec13:chunk0]. Overall, Alix acts as a brake on paraptosis, especially by dampening IGF1R-associated MAPK/JNK signaling and opposing ROS-linked paraptotic execution.

---

## Q9: How does mitochondrial dysfunction contribute to paraptosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Molecular regulators
- Retrieval strength: MEDIUM
- Evidence diversity: MEDIUM
- Top1 score: 0.6400
- Top5 avg score: 0.5329
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does mitochondrial dysfunction contribute to paraptosis?

### GPT answer

Mitochondrial dysfunction can drive **paraptosis** by promoting the characteristic cytoplasmic vacuolization and stress signaling that distinguish this non-apoptotic cell death pathway.

Mechanistically:

- **Mitochondrial swelling and vacuole formation:** Loss of mitochondrial ion homeostasis, permeability transition, or osmotic imbalance causes mitochondrial dilation. These swollen mitochondria can appear as large cytoplasmic vacuoles, a hallmark of paraptosis.

- **Reactive oxygen species production:** Damaged mitochondria generate excess ROS, which oxidize proteins, lipids, and organelle membranes. ROS can amplify ER stress and activate stress kinases such as MAPK/JNK pathways that support paraptotic death.

- **ATP depletion:** Impaired oxidative phosphorylation reduces ATP production. Energy failure compromises protein folding, ion pumps, and organelle homeostasis, favoring ER and mitochondrial dilation rather than orderly apoptotic dismantling.

- **Calcium dysregulation:** Mitochondrial dysfunction disrupts Ca²⁺ buffering. Mitochondrial Ca²⁺ overload and abnormal ER–mitochondria Ca²⁺ exchange can promote both mitochondrial swelling and ER stress.

- **ER stress amplification:** Because mitochondria and ER are functionally coupled, mitochondrial damage can worsen unfolded protein response signaling and proteostasis failure, which are commonly involved in paraptosis.

Importantly, paraptosis usually occurs **without classical apoptotic features** such as caspase activation, chromatin condensation, or apoptotic body formation. Thus, mitochondrial dysfunction contributes mainly through **swelling, ROS, calcium imbalance, ATP loss, and ER-stress amplification**, rather than through the canonical cytochrome-c/caspase apoptotic pathway.

### RAG answer

Mitochondrial dysfunction contributes to paraptosis by converting ER-derived Ca²⁺ flux into a self-amplifying mitochondrial–ER injury loop: mitochondrial Ca²⁺ overload triggers ROS production, loss of mitochondrial membrane potential, impaired ATP generation, mitochondrial swelling/dilation, and secondary worsening of ER Ca²⁺ depletion and ER stress, culminating in the large ER/mitochondrial vacuoles characteristic of paraptosis [PMC7873879:sec19:chunk1; PMC7873879:abstract:chunk0].
Mechanistically, Ca²⁺ released from the ER through IP₃Rs or RyRs reaches mitochondria at mitochondria-associated ER membranes, enters through VDAC and the MCU complex, and can initially support mitochondrial metabolism. When the flux is prolonged or excessive, however, mitochondrial Ca²⁺ overload promotes ROS generation and mPTP opening, causing water and solute influx into the matrix, mitochondrial swelling, dissipation of mitochondrial membrane potential, uncoupling of oxidative phosphorylation, and metabolic collapse [PMC7873879:sec19:chunk0; PMC7873879:sec19:chunk1].
This mitochondrial failure feeds back onto the ER. Loss of membrane potential reduces mitochondrial Ca²⁺ retention, raising cytosolic Ca²⁺, while ATP shortage limits SERCA-dependent Ca²⁺ reuptake into the ER. The resulting ER Ca²⁺ depletion promotes misfolded-protein accumulation and osmotic ER dilation; swollen ER compartments can then fuse into large vacuoles occupying much of the cytoplasm [PMC7873879:sec19:chunk1]. Thus, mitochondrial dysfunction is not just a consequence of paraptosis but helps drive the paraptotic phenotype of mitochondrial and ER dilation [PMC7873879:sec0:chunk0; PMC7873879:sec17:chunk0].
Experimental observations support this model: mitochondrial Ca²⁺ overload is commonly reported across multiple paraptosis-inducing treatments, and inhibition of MCU or VDAC-mediated Ca²⁺ uptake attenuates mitochondrial dilation, ER stress/dilation, and subsequent paraptotic cell death in several systems [PMC7873879:sec17:chunk1]. In δ-tocotrienol-treated melanoma cells, mitochondrial ROS generation and Ca²⁺ transfer through IP₃R/VDAC were functionally linked to reduced viability, vacuole formation, and MAPK activation, further tying mitochondrial dysfunction to the paraptotic cascade [PMC8197726:sec16:chunk1].

---

## Q10: Can paraptosis overcome chemotherapy resistance?

- Expected group: HIGH (RAG should clearly outperform GPT) / Translational
- Retrieval strength: HIGH
- Evidence diversity: HIGH
- Top1 score: 1.0000
- Top5 avg score: 0.5370
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: Can paraptosis overcome chemotherapy resistance?

### GPT answer

Yes—**in principle, paraptosis can help overcome some forms of chemotherapy resistance**, especially resistance caused by defective apoptosis.

Many chemoresistant cancers evade treatment by blocking apoptosis through mechanisms such as p53 loss, Bcl-2 overexpression, caspase inhibition, or impaired mitochondrial apoptotic signaling. **Paraptosis is a non-apoptotic cell death pathway**, so it can bypass some of these blocks.

Mechanistically, paraptosis is typically associated with:

- Extensive **endoplasmic reticulum and/or mitochondrial swelling**
- **Cytoplasmic vacuolization**
- **ER stress** and unfolded protein response activation
- Disrupted protein homeostasis or proteasome stress
- Often **MAPK signaling involvement**
- Little or no caspase activation, DNA fragmentation, or apoptotic body formation

Because it does not rely on classical apoptotic caspase pathways, inducing paraptosis may kill tumor cells that are apoptosis-resistant.

However, this is **not guaranteed**. Its effectiveness depends on the cancer type, the specific resistance mechanism, and the drug used. Most evidence is still preclinical, so while paraptosis is a promising strategy to bypass chemotherapy resistance, it is not yet a broadly established clinical solution.

### RAG answer

Yes—paraptosis can potentially overcome chemotherapy resistance, especially when resistance is driven by failure of apoptosis, but the evidence is mainly preclinical and translational rather than clinically established. Because paraptosis is caspase-independent and mechanistically distinct from classical apoptosis, it may bypass apoptotic resistance mechanisms that limit conventional chemotherapy and radiotherapy [paper_8b08118292ccc1f6:abstract:chunk0].
Mechanistically, paraptosis-inducing strategies appear to exploit ER stress, disrupted Ca²⁺ homeostasis, mitochondrial dysfunction, ROS-mediated oxidative stress, MAPK hyperactivation, and cytoplasmic vacuolization to kill resistant tumor cells. For example, α-hederin induces paraptosis in 5-fluorouracil-resistant HT-29 colorectal cancer cells through the PLCβ3–IP3R–Ca²⁺–PKCα pathway, while copper complexes inhibit multiple cancer cell lines, including cisplatin-resistant ovarian and doxorubicin-resistant colon carcinoma variants, with ROS generation, mitochondrial membrane potential loss, G2/M arrest, and paraptosis [PMC11533606:sec20:chunk0].
Combination therapy is a recurring theme. Paraptosis inducers have been reported to sensitize resistant contexts such as bortezomib-insensitive or bortezomib-resistant tumor cells, cisplatin-treated settings, paclitaxel-resistant H1299 lung cancer cells, and cisplatin-resistant bladder cancer cells when paired with agents such as ISRIB, nutlin-3, Paris saponin II, honokiol, or jolkinolide B [PMC11546839:sec29:chunk0; PMC11533606:sec19:chunk0]. Similar logic is described for proteasome inhibitor resistance, where inducing paraptotic death may enhance bortezomib sensitivity in colon cancer models [PMC10792489:sec11:chunk0].
Nanomedicine is also being explored to deliver paraptosis-inducing agents selectively to apoptosis-resistant tumors, most often through ROS-driven oxidative stress leading to organelle swelling and cytoplasmic vacuolization [PMC11533606:sec22:chunk0]. In breast cancer contexts, paraptosis inducers are described as capable of triggering death in TNBC through ER stress and calcium-homeostasis disruption, with broader therapeutic potential in chemoresistance, though biomarkers and specific signaling definitions remain underdeveloped [PMC12685561:sec0:chunk1; PMC12685561:sec25:chunk0].
So, paraptosis is a plausible and actively investigated route to overcome chemotherapy resistance, particularly apoptosis-linked resistance, but current support rests largely on cell and xenograft studies; clinical validation, biomarkers, and standardized pathway definitions are still insufficient [PMC12685561:sec25:chunk0].

---

## Q11: Can paraptosis be exploited as an anticancer strategy?

- Expected group: HIGH (RAG should clearly outperform GPT) / Translational
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4150
- Coverage: 0.6667
- Evidence count: 8
- Normalized retrieval query: Can paraptosis be exploited as an anticancer strategy?

### GPT answer

Yes. **Paraptosis can potentially be exploited as an anticancer strategy**, especially in tumors that resist apoptosis.

Paraptosis is a form of regulated, non-apoptotic cell death characterized by:

- Extensive **cytoplasmic vacuolization**
- Swelling of the **endoplasmic reticulum and/or mitochondria**
- Lack of classical apoptotic features such as caspase activation, DNA fragmentation, or membrane blebbing
- Often involvement of **ER stress**, **mitochondrial dysfunction**, **reactive oxygen species**, **MAPK signaling**, and disrupted protein homeostasis

Mechanistically, inducing paraptosis may be useful because many cancers evade apoptosis through mutations or overexpression of proteins such as **p53, BCL-2, BCL-XL, MCL-1, or caspase inhibitors**. A drug that triggers paraptosis could bypass these apoptosis-resistance mechanisms.

Potential anticancer approaches include agents that:

- Cause severe **ER stress** or unfolded protein response overload
- Disrupt **proteasome function** or protein folding
- Induce **mitochondrial swelling and dysfunction**
- Increase **ROS** beyond a tolerable threshold
- Hyperactivate signaling pathways such as **MAPK/ERK or JNK** in a death-promoting context

However, this strategy is still not fully established clinically. Key challenges include:

- Paraptosis is less well molecularly defined than apoptosis
- Specific biomarkers are limited
- Selective induction in cancer cells over normal cells is difficult
- Excessive ER or mitochondrial stress could damage healthy tissues

So, **paraptosis is a promising anticancer concept, particularly for apoptosis-resistant cancers, but it remains mainly experimental and requires better mechanistic definition, selective inducers, and validated biomarkers before broad clinical use.**

### RAG answer

Yes—paraptosis can be exploited as an anticancer strategy, particularly for tumors that evade apoptosis or are resistant to conventional chemo/radiotherapy. Its appeal is that paraptosis is mechanistically distinct from classical apoptosis: it is caspase-independent, lacks typical apoptotic nuclear changes, and is characterized by cytoplasmic vacuolization with ER and/or mitochondrial swelling, often involving MAPK signaling rather than canonical apoptotic machinery [paper_8b08118292ccc1f6:abstract:chunk0]. Because it does not directly overlap with common apoptosis-resistance mechanisms, inducing paraptosis is proposed as a way to bypass treatment resistance [PMC11546839:sec23:chunk0].
Mechanistically, many paraptosis-inducing anticancer approaches converge on cellular proteostasis and organelle stress: reduced protein degradation/proteasome inhibition, disturbed autophagic flux, ER stress/UPR activation, Ca²⁺ or ion imbalance, sulfhydryl/redox disruption, and ROS generation can drive ER/mitochondrial swelling and cytoplasmic vacuolization, culminating in cancer cell death [PMC11533606:sec18:chunk0; PMC10789732:abstract:chunk0]. Nanomedicine strategies are especially relevant because they can selectively deliver paraptosis-inducing agents to tumors; many reported systems act through ROS-mediated oxidative stress leading to vacuolization and organelle swelling [PMC11533606:sec22:chunk0].
There is also preclinical support for practical therapeutic designs. Reported nanomedicines include Cu(HQ)₂-generating micelles that inhibit the proteasome, silver nanoparticles that induce ROS, mitochondrial/ER dilation and MAPK activity, Cu²⁺-coordinated morusin/doxorubicin systems that combine paraptotic and apoptotic death, and Cu(DDC)₂ nanoparticles active in drug-resistant prostate cancer cells [PMC10308048:sec38:chunk0]. These examples support the concept that paraptosis could be used alone or combined with standard cytotoxic agents to address chemoresistance [PMC12685561:sec25:chunk0].
A second rationale is immunologic: paraptosis may increase tumor immunogenicity, remodel the tumor microenvironment, and promote antitumor T-cell or type I interferon–linked responses, suggesting possible synergy with immunotherapy [PMC12685561:sec25:chunk0; PMC11606808:sec3:chunk1]. However, the clinical case is still immature. The retrieved literature notes unresolved problems, including limited biomarkers, incompletely defined signaling specificity, reliance on cytoplasmic vacuolization for recognition, and insufficient understanding of how paraptosis interacts with immune checkpoint blockade or other immunotherapies [PMC12685561:sec25:chunk0]. Thus, paraptosis is a promising anticancer strategy, but not yet a clinically established one.

---

## Q12: What evidence links paraptosis to breast cancer prognosis?

- Expected group: HIGH (RAG should clearly outperform GPT) / Translational
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9717
- Top5 avg score: 0.7958
- Coverage: 0.8000
- Evidence count: 8
- Normalized retrieval query: What evidence links paraptosis to breast cancer prognosis?

### GPT answer

Evidence linking paraptosis to breast cancer prognosis is mainly **indirect but consistent**:

- **Gene-expression studies:** Tumors with different expression patterns of **paraptosis-related genes** can be stratified into prognostic risk groups. These risk scores have been reported to correlate with **overall survival**, and in some analyses remain prognostic after adjustment for clinical variables.

- **Association with aggressive biology:** High-risk paraptosis-related signatures often align with pathways involving **ER stress, mitochondrial dysfunction, MAPK/JNK signaling, oxidative stress, proteostasis stress, and immune-microenvironment changes**—features linked to tumor progression and treatment resistance.

- **Therapeutic relevance in models:** Several compounds can induce paraptosis-like death in breast cancer cell lines, including apoptosis-resistant cells. This suggests that the ability or inability of tumor cells to undergo paraptosis may influence treatment response.

- **Immune and subtype correlations:** Paraptosis-related signatures have been associated with immune infiltration patterns and breast cancer molecular subtypes, which themselves influence prognosis.

However, the key limitation is that **paraptosis is rarely measured directly in patient tumors**. Most prognostic evidence comes from **bioinformatic gene-signature analyses**, not direct histologic proof that paraptotic cell death rates determine patient outcomes. Thus, paraptosis is best viewed as a **prognosis-associated stress/death pathway**, not yet a validated clinical prognostic marker.

### RAG answer

Paraptosis is linked to breast cancer prognosis mainly through transcriptomic risk modeling of paraptosis-related genes: a paraptosis-related risk score (PRRS) stratified patients into prognostic groups, with low PRRS associated with better prognosis, lower tumor purity, and greater immune-cell infiltration [PMC12685561:abstract:chunk0].
Mechanistically, the evidence suggests a pathway from paraptosis-related gene expression → altered tumor immune microenvironment → survival differences. In the reported model, six genes—PI4KB, HSPB8, USP10, LCK, GPR153, and NT5C—were retained after Cox/LASSO-based selection to construct the PRRS, and these genes showed prognostic association with overall survival in TCGA-BRCA analyses [PMC12685561:sec18:chunk0]. The study concludes that these paraptosis-related biomarkers correlate with breast cancer prognosis, clinical features, and immune infiltration [PMC12685561:sec26:chunk0].
The prognostic signal appears immunologically patterned: low-risk tumors showed enhanced immune responses, higher immune checkpoint expression, and immune activation, whereas high-risk tumors had lower expression of immune-associated genes and reduced immune-cell presence, which the authors link to poorer prognosis [PMC12685561:sec25:chunk1]. Consistently, differentially expressed genes between PRRS groups were enriched in cytokine–cytokine receptor interactions, hematopoietic lineage, T-cell regulation, PD1 expression, and regulation of T-cell cytokine activity, supporting an immune-microenvironment basis for the prognostic association [PMC12685561:sec20:chunk0].
There is also limited functional support for one component of the signature: PI4KB was highly expressed in breast cancer, and PI4KB knockdown suppressed breast cancer cell proliferation and migration in vitro, suggesting that at least one paraptosis-related prognostic gene may contribute to aggressive tumor behavior [PMC12685561:abstract:chunk0]. However, the retrieved evidence is largely from one integrative bioinformatics study plus in vitro validation of PI4KB; it supports an association between paraptosis-related gene programs and prognosis, but does not fully establish paraptosis itself as a causal determinant of breast cancer outcome.

---

## Q13: What are the defining features of paraptosis?

- Expected group: MEDIUM (GPT can answer partially; RAG should be more specific) / Reviews
- Retrieval strength: HIGH
- Evidence diversity: HIGH
- Top1 score: 0.9060
- Top5 avg score: 0.5200
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What are the defining features of paraptosis?

### GPT answer

Paraptosis is a form of regulated, non-apoptotic cell death defined mainly by:

- **Extensive cytoplasmic vacuolization**: large vacuoles form, typically from **swelling/dilation of the endoplasmic reticulum and/or mitochondria**.
- **Absence of classic apoptosis features**:
  - no prominent chromatin condensation
  - no nuclear fragmentation
  - no apoptotic bodies
  - little or no caspase activation
  - generally not blocked by caspase inhibitors
- **No primary autophagic morphology**:
  - vacuoles are not typical double-membrane autophagosomes
  - death is not primarily lysosome-driven autophagy.
- **Dependence on new protein synthesis**: often inhibited by cycloheximide or other protein synthesis blockers.
- **Association with ER stress and proteotoxic stress**: unfolded protein response, ER swelling, and disturbed protein handling are common.
- **Mitochondrial dysfunction may occur**, but without the canonical apoptotic caspase cascade.
- **Plasma membrane integrity is relatively preserved until late**, unlike primary necrosis.

Mechanistically, paraptosis is often linked to **MAPK signaling**, ER/mitochondrial swelling, disrupted proteostasis, and progressive cytoplasmic vacuole accumulation leading to cell death.

### RAG answer

Paraptosis is defined primarily as a non-apoptotic form of regulated/programmed cell death marked by extensive cytoplasmic vacuolation, typically arising from swelling/dilatation of the endoplasmic reticulum and/or mitochondria [PMC11546839:sec8:chunk0]. Morphologically, this contrasts with classical apoptosis: paraptotic cells show large cytoplasmic vacuoles rather than cell shrinkage, chromatin condensation, apoptotic bodies, or typical apoptotic nuclear changes [paper_8b08118292ccc1f6:abstract:chunk0].
Biochemically, paraptosis is characterized by the absence of canonical apoptotic execution: it does not require caspase activation and is not associated with DNA fragmentation [PMC10474147:sec13:chunk0]. Several reviews also distinguish it from autophagy and other cell-death modes because the vacuoles are linked to ER/mitochondrial dilation rather than classical autophagic vacuole formation [paper_25e3ec5913603f7c:abstract:chunk0; paper_70f5edd25bc38a8c:abstract:chunk0].
Mechanistically, the retrieved evidence links paraptosis to organelle stress and homeostatic disruption: impaired proteostasis, altered thiol/sulfhydryl balance, ion imbalance, mitochondrial Ca²⁺ overload, and reactive oxygen species can converge on ER/mitochondrial dysfunction and swelling [PMC10474147:sec13:chunk0; PMC10789732:abstract:chunk0]. MAPK-related signaling is also described as important, with paraptosis operating independently of the caspase system and involving pathways such as MEK/JNK in some contexts [PMC10474147:sec13:chunk0].
A recently proposed additional morphological feature is the “paraptosome,” described as a high-density spherical structure originating from the Golgi apparatus during paraptotic cell death; however, this appears to be a newer proposed marker rather than a universally established defining criterion [paper_439f89994063b5e5:abstract:chunk0].

---

## Q14: How is paraptosis different from apoptosis?

- Expected group: MEDIUM (GPT can answer partially; RAG should be more specific) / Reviews
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.5307
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How is paraptosis different from apoptosis?

### GPT answer

Paraptosis is a form of programmed cell death that is mechanistically and morphologically distinct from apoptosis.

Key differences:

- **Caspase dependence**
  - **Apoptosis:** usually depends on caspase activation, especially caspase-3, -8, or -9.
  - **Paraptosis:** generally **caspase-independent** and is not blocked by caspase inhibitors.

- **Cell morphology**
  - **Apoptosis:** cell shrinkage, chromatin condensation, nuclear fragmentation, membrane blebbing, and apoptotic body formation.
  - **Paraptosis:** prominent **cytoplasmic vacuolization**, usually from swelling of the **endoplasmic reticulum and/or mitochondria**, without classic apoptotic bodies.

- **Nuclear changes**
  - **Apoptosis:** marked DNA fragmentation and chromatin condensation.
  - **Paraptosis:** lacks prominent DNA laddering, pyknosis, and nuclear fragmentation.

- **Mitochondrial role**
  - **Apoptosis:** often involves mitochondrial outer membrane permeabilization, cytochrome c release, and caspase activation.
  - **Paraptosis:** may involve mitochondrial swelling and dysfunction but not the canonical cytochrome c–caspase cascade.

- **Regulation**
  - **Apoptosis:** controlled by BCL-2 family proteins, death receptors, and caspases.
  - **Paraptosis:** often associated with **MAPK signaling**, ER stress, disrupted proteostasis, and may require new protein synthesis.

In short: **apoptosis is a caspase-driven, nuclear-fragmenting, cell-shrinking death program, whereas paraptosis is a caspase-independent death process characterized mainly by extensive cytoplasmic vacuolization from organelle swelling.**

### RAG answer

Paraptosis differs from apoptosis mainly in morphology and execution mechanism: apoptosis is a caspase-driven program with cell/nuclear shrinkage, chromatin condensation, DNA fragmentation, and membrane-bound apoptotic bodies, whereas paraptosis is caspase-independent and dominated by extensive cytoplasmic vacuolization caused by swelling/dilatation of the endoplasmic reticulum and mitochondria, without typical apoptotic nuclear changes or apoptotic body formation [PMC11546839:sec2:chunk0; PMC10474147:sec13:chunk0].
Mechanistically, apoptosis proceeds through intrinsic or extrinsic pathways that activate initiator caspases and then effector caspases to dismantle the cell; apoptotic bodies are then phagocytosed, limiting inflammatory release [PMC11546839:sec2:chunk0]. Paraptosis, by contrast, does not require caspase activation or DNA fragmentation and is often linked to MAPK signaling—such as MEK/JNK/p38-related pathways—together with ER stress, proteostasis disruption, ROS generation, Ca²⁺ imbalance, and ER–mitochondrial dysfunction [PMC10308048:sec15:chunk0; PMC11294602:sec17:chunk0; PMC10474147:sec13:chunk0].
Phenotypically, apoptosis is a “shrink-and-package” death mode, while paraptosis is more of a “swell-and-vacuolate” death mode: large cytoplasmic vacuoles arise from ER and mitochondrial dilation, and cells lack classic apoptotic hallmarks such as DNA condensation/breakage, membrane blistering, and apoptotic bodies [PMC11294602:sec17:chunk0]. This distinction matters in cancer because paraptosis may kill cells that have acquired resistance to apoptosis, making it a potential therapeutic route when conventional apoptosis-based killing is evaded [PMC10308048:abstract:chunk0].

---

## Q15: How is paraptosis different from necroptosis?

- Expected group: MEDIUM (GPT can answer partially; RAG should be more specific) / Reviews
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4343
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How is paraptosis different from necroptosis?

### GPT answer

Paraptosis and necroptosis are both non-apoptotic forms of programmed cell death, but they differ mechanistically and morphologically.

| Feature | Paraptosis | Necroptosis |
|---|---|---|
| Core morphology | Extensive cytoplasmic vacuolization, usually from swelling of the endoplasmic reticulum and/or mitochondria | Cell swelling, plasma membrane rupture, necrotic morphology |
| Main molecular pathway | Less well-defined; often associated with MAPK signaling, ER stress, proteotoxic stress, and new protein synthesis | Well-defined RIPK1–RIPK3–MLKL pathway |
| Key executors | No single canonical executor established | MLKL is the major executioner; phosphorylated MLKL disrupts the plasma membrane |
| Caspase dependence | Caspase-independent | Caspase-independent, often occurs when caspase-8 is inhibited or insufficient |
| Membrane integrity | Plasma membrane disruption is not the defining early event | Plasma membrane permeabilization/rupture is central |
| Inflammation | Variable; not classically defined as strongly inflammatory | Typically pro-inflammatory due to membrane rupture and DAMP release |
| Inhibitors | Often reduced by protein synthesis inhibitors such as cycloheximide in experimental systems | Inhibited by RIPK1 inhibitors, RIPK3 inhibition/loss, or MLKL inhibition/loss |

Mechanistically, **necroptosis is a regulated necrotic death program driven by RIPK3-mediated MLKL activation**, leading to membrane rupture. **Paraptosis is characterized mainly by ER/mitochondrial swelling and cytoplasmic vacuolation, without the canonical RIPK3–MLKL machinery**, and its molecular definition is less standardized.

### RAG answer

Paraptosis differs from necroptosis mainly in its morphology and upstream execution machinery: paraptosis is a vacuolating, organelle-stress–associated regulated cell death marked by ER and mitochondrial swelling, whereas necroptosis is a programmed necrotic pathway mediated by RIP1/RIP3/MLKL signaling [PMC10474147:sec13:chunk0] [PMC10308048:sec11:chunk0].
Mechanistically, paraptosis is caspase-independent but is linked to disrupted proteostasis, altered thiol or ion homeostasis, ER stress, Ca²⁺ flux between ER and mitochondria, and MAPK-related signaling such as MEK/JNK downstream of IGF-IR; it can be suppressed by AIP-1/Alix and cycloheximide in some contexts [PMC10474147:sec13:chunk0] [PMC7941236:sec5:chunk0]. Necroptosis is also caspase-independent, but its defining axis is RIP1, RIP3, and MLKL, and it can be inhibited by necrostatin-1 through blockade of RIPK1 activity [PMC10308048:sec11:chunk0].
Morphologically, paraptosis lacks classical apoptotic nuclear changes such as DNA fragmentation, chromatin condensation, nuclear fragmentation, and apoptotic body formation; instead, it shows large cytoplasmic vacuoles caused by ER and mitochondrial dilation, followed by loss of plasma membrane integrity [PMC10474147:sec13:chunk0] [PMC11546839:sec8:chunk0] [PMC11606808:sec1:chunk0]. Necroptosis, by contrast, is described in the retrieved evidence as a programmed form of necrotic cell death, with necrosis-like morphology and activation by signals such as TNFRs, PRRs, TCRs, chemotherapeutic drugs, and stresses such as hypoxia [PMC10308048:sec11:chunk0].
So, although both are non-apoptotic/caspase-independent death modes, paraptosis is best distinguished by ER–mitochondrial vacuolization and proteostasis/organelle stress, while necroptosis is defined by RIPK1–RIPK3–MLKL programmed necrotic signaling.

---

## Q16: How is paraptosis different from ferroptosis?

- Expected group: MEDIUM (GPT can answer partially; RAG should be more specific) / Reviews
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.9456
- Top5 avg score: 0.3995
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How is paraptosis different from ferroptosis?

### GPT answer

Paraptosis and ferroptosis are both non-apoptotic forms of regulated cell death, but they differ mechanistically and morphologically.

| Feature | Paraptosis | Ferroptosis |
|---|---|---|
| Core mechanism | Cytoplasmic vacuolization from swelling of endoplasmic reticulum and/or mitochondria | Iron-dependent accumulation of lipid peroxides in cell membranes |
| Main biochemical driver | Often linked to proteotoxic stress, disturbed ER/mitochondrial homeostasis, MAPK signaling, and impaired protein degradation | Failure of antioxidant defenses, especially glutathione/GPX4, leading to peroxidation of PUFA-containing phospholipids |
| Morphology | Large cytoplasmic vacuoles, ER dilation, mitochondrial swelling | Shrunken mitochondria with dense membranes; lipid membrane damage |
| Caspase dependence | Caspase-independent | Caspase-independent |
| DNA fragmentation | Typically absent | Typically absent |
| Key inhibitors | Often blocked by protein synthesis inhibitors or MAPK pathway modulation, depending on context | Blocked by iron chelators, lipophilic antioxidants, ferrostatin-1, liproxstatin-1, or GPX4 preservation |
| Role of iron | Not a defining feature | Essential defining feature |
| Lipid peroxidation | Not central | Central |

In short: **paraptosis is mainly a vacuolating, ER/mitochondrial swelling-type cell death**, whereas **ferroptosis is an iron-driven lipid peroxidation-mediated membrane damage process**.

### RAG answer

Paraptosis differs from ferroptosis primarily in its trigger, morphology, and execution chemistry: paraptosis is a caspase-independent programmed death marked by ER/mitochondrial swelling and large cytoplasmic vacuoles, whereas ferroptosis is iron-dependent death driven by lipid peroxide accumulation and oxidative membrane damage [PMC10474147:sec13:chunk0; PMC10474147:sec12:chunk0].
Mechanistically, paraptosis is linked to disturbed proteostasis or ion homeostasis: misfolded protein accumulation in the ER can generate osmotic ER distension, ER Ca²⁺ release, mitochondrial Ca²⁺ overload, and mitochondrial dilation; IGF-IR–MEK/JNK signaling has also been associated with its promotion [PMC10474147:sec13:chunk0]. Ferroptosis instead follows a redox–lipid pathway: inhibition of system Xc⁻ reduces cystine import and glutathione synthesis, weakening GPX4-dependent detoxification of lipid peroxides; iron and ROS then amplify lipid peroxidation, leading to membrane damage [PMC9371342:sec17:chunk0; PMC10474147:sec12:chunk0].
Morphologically, the contrast is almost opposite. Paraptotic cells show cytoplasmic vacuolization from swelling of the ER and mitochondria [PMC10474147:sec13:chunk0]. Ferroptotic cells characteristically show shrunken mitochondria with increased membrane density and reduced or absent cristae, without the cytoplasmic/organelle expansion typical of paraptosis [PMC9371342:sec17:chunk0; PMC10669395:sec5:chunk1].
Pharmacologically, ferroptosis can be blocked by ferrostatin-1, iron chelators, and antioxidants, consistent with its dependence on iron and lipid peroxidation [PMC10308048:sec8:chunk0]. The retrieved evidence does not provide comparably specific inhibitors for paraptosis, beyond noting pathway regulation such as AIP-1/Alix-mediated inhibition and MEK/JNK involvement [PMC10474147:sec13:chunk0].

---

## Q17: What biomarkers are commonly used to identify paraptosis?

- Expected group: MEDIUM (GPT can answer partially; RAG should be more specific) / Reviews
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.7358
- Top5 avg score: 0.5420
- Coverage: 0.5000
- Evidence count: 8
- Normalized retrieval query: What biomarkers are commonly used to identify paraptosis?

### GPT answer

Paraptosis has **no single definitive biomarker**; it is usually identified by a combination of morphology and exclusion of apoptosis/autophagy/necroptosis.

Commonly used indicators include:

- **Massive cytoplasmic vacuolization**: large vacuoles arising mainly from **swollen endoplasmic reticulum and/or mitochondria**.
- **ER swelling/ER stress markers**: increased **GRP78/BiP, CHOP, ATF4, phosphorylated PERK/eIF2α**, often with ER marker colocalization such as **calnexin** or **PDI**.
- **Mitochondrial dilation/dysfunction**: swollen mitochondria, altered mitochondrial membrane potential, sometimes increased ROS.
- **MAPK pathway activation**: phosphorylation/activation of **ERK, JNK, and/or p38 MAPK** is frequently reported.
- **Proteostasis stress**: accumulation of misfolded/ubiquitinated proteins and proteasome dysfunction.
- **Dependence on protein synthesis**: inhibition by **cycloheximide** is often used as supportive evidence.
- **Absence of apoptotic markers**: little or no **caspase-3 activation, PARP cleavage, DNA laddering, chromatin condensation, or apoptotic bodies**; not rescued by pan-caspase inhibitors such as z-VAD-fmk.
- **Lack of canonical autophagy features**: vacuoles are not typical autophagosomes; LC3-II/p62 changes are not the defining feature.

Mechanistically, paraptosis is generally characterized by **ER/mitochondrial swelling driven by proteotoxic stress, ER stress, ROS/Ca²⁺ imbalance, and MAPK signaling**, rather than caspase-dependent apoptosis.

### RAG answer

There are no universally accepted, pathway-defining biomarkers for paraptosis. In practice, paraptosis is identified mainly by morphology—prominent cytoplasmic vacuolization, typically with endoplasmic reticulum and/or mitochondrial swelling—combined with exclusion of other regulated cell-death programs such as apoptosis or autophagy [PMC12685561:sec25:chunk0; PMC12929809:sec1:chunk0].
Mechanistically, studies often look for MAPK pathway involvement because paraptosis is described as depending on MAPK pathway activation and being accompanied by cytoplasmic vacuolation [PMC12928938:sec22:chunk0]. However, MAPK activation is not a specific standalone biomarker; it is better interpreted as supportive evidence in the right morphological and experimental context.
Several molecules have been proposed as paraptosis-associated regulators or disease-specific biomarkers, but they are not general identifiers of paraptosis. Examples include Alix, VDAC1, and MCU as implicated regulators, though no definitive executor or minimal molecular signature has been established [PMC12929809:sec1:chunk0]. Disease-specific transcriptomic studies have nominated markers such as ITPR3, MAPK1, and MAPK8 in meningioma [PMC12746925:sec16:chunk0], CDKN3, PEBP1, TNFRSF19, and PHB in lung adenocarcinoma [PMC12928938:abstract:chunk0], and PCNPP3 and ELOA in recurrent miscarriage [PMC12626843:abstract:chunk0].
So, the commonly used “biomarkers” are not molecular markers in the strict sense; they are a diagnostic pattern: cytoplasmic vacuolization → ER/mitochondrial swelling → MAPK-related signaling support → absence of canonical apoptosis/autophagy markers or dependence. The retrieved evidence supports that the field still lacks a robust biomarker analogous to cleaved caspase-3 for apoptosis or LC3-II for autophagy [PMC12929809:sec1:chunk0].

---

## Q18: What organelles are involved in paraptosis?

- Expected group: MEDIUM (GPT can answer partially; RAG should be more specific) / Reviews
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.5245
- Coverage: 0.5000
- Evidence count: 8
- Normalized retrieval query: What organelles are involved in paraptosis?

### GPT answer

Paraptosis mainly involves swelling and vacuolization of:

- **Endoplasmic reticulum (ER)** — ER dilation is a hallmark; often linked to ER stress and unfolded protein response.
- **Mitochondria** — mitochondrial swelling, membrane dysfunction, and altered calcium/ROS signaling can contribute.
- **Sometimes the Golgi apparatus** — Golgi dilation/fragmentation may be observed in some models, but it is less central than ER and mitochondria.

Unlike apoptosis, paraptosis typically does **not** feature prominent nuclear condensation/fragmentation or caspase-dependent organelle dismantling.

### RAG answer

The main organelles involved in paraptosis are the endoplasmic reticulum (ER) and mitochondria. Paraptosis is defined morphologically by cytoplasmic vacuolization that arises from dilation/swelling of the ER and/or mitochondria, with mitochondrial swelling and loss of cristae often appearing in later phases [PMC7873879:sec0:chunk0; PMC11533606:sec1:chunk0; PMC11546839:sec9:chunk0].
Mechanistically, the ER–mitochondria axis appears central: ER stress, unfolded/misfolded protein accumulation, disturbed ion homeostasis, and especially Ca²⁺ transfer from ER to mitochondria can drive ER dilation and mitochondrial Ca²⁺ overload, leading to mitochondrial dilation and dysfunction [PMC7873879:abstract:chunk0; PMC11533606:sec17:chunk0]. ROS amplification and impaired proteasome activity further reinforce ER stress and mitochondrial dysfunction during the paraptotic program [PMC11533606:sec17:chunk0].
Additional intracellular compartments may also participate or be affected. A recent report describes a putative “paraptosome” originating from the Golgi apparatus, associated with Golgi stress/disintegration and disruption of Golgi function during paraptosis [paper_439f89994063b5e5:abstract:chunk0]. The same study reports that paraptosis inducers can alter autophagosomes and lysosomes as well, although these are presented as organelle alterations rather than the defining source of paraptotic vacuoles [paper_439f89994063b5e5:abstract:chunk0].
So, the core organelles are ER and mitochondria; the Golgi apparatus may contribute via Golgi-derived paraptosome formation, and autophagosomes/lysosomes can be secondarily altered in some paraptosis models.

---

## Q19: Is paraptosis caspase dependent?

- Expected group: MEDIUM (GPT can answer partially; RAG should be more specific) / Reviews
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.8779
- Top5 avg score: 0.4254
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: Is paraptosis caspase dependent?

### GPT answer

No. **Paraptosis is generally caspase-independent**.

Mechanistically, paraptosis is a non-apoptotic programmed cell death characterized by **extensive cytoplasmic vacuolization**, usually from **endoplasmic reticulum and/or mitochondrial swelling**, without classic apoptotic features such as DNA fragmentation, membrane blebbing, or caspase-3 activation. It is typically **not blocked by pan-caspase inhibitors** like z-VAD-fmk.

It is more often associated with pathways such as **MAPK signaling**, **ER stress**, **proteasome dysfunction**, and disrupted protein homeostasis.

### RAG answer

No. Paraptosis is generally described as a caspase-independent programmed cell death pathway. Unlike apoptosis, it does not require caspase activation, and caspase inhibition is reported to be ineffective at blocking paraptotic cell death [PMC11546839:sec11:chunk0]. Multiple reviews distinguish it from classical apoptosis on this basis: paraptosis lacks typical apoptotic nuclear/morphologic features and its signaling operates independently of the caspase system [paper_8b08118292ccc1f6:abstract:chunk0].
Mechanistically, paraptosis is more often linked to cytoplasmic vacuolization arising from ER and/or mitochondrial swelling, with involvement of MAPK signaling, ER stress, proteostasis disruption, ROS generation, Ca²⁺ imbalance, and related metabolic stress rather than an apoptotic caspase cascade [PMC10308048:sec15:chunk0; PMC11294602:sec17:chunk0]. It may require active transcription and translation, since inhibitors such as actinomycin D or cycloheximide can block it, but this requirement is distinct from caspase dependence [PMC11546839:sec11:chunk0].
So, the concise answer is: paraptosis is caspase-independent, not caspase-dependent.

---

## Q20: What signaling pathways are most frequently associated with paraptosis?

- Expected group: MEDIUM (GPT can answer partially; RAG should be more specific) / Reviews
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.3997
- Coverage: 0.4000
- Evidence count: 8
- Normalized retrieval query: What signaling pathways are most frequently associated with paraptosis?

### GPT answer

Paraptosis is most frequently associated with these signaling mechanisms:

- **MAPK pathways**: especially **ERK**, **JNK**, and **p38 MAPK** activation. These are among the most commonly reported drivers and can promote cytoplasmic vacuolization and stress signaling.

- **Endoplasmic reticulum stress / unfolded protein response (UPR)**: involving pathways such as **PERK–eIF2α–ATF4/CHOP**, **IRE1**, and **ATF6**. ER dilation and protein-folding stress are characteristic features.

- **ROS-mediated signaling**: increased **reactive oxygen species** can trigger ER stress, mitochondrial dysfunction, and MAPK activation.

- **Calcium signaling dysregulation**: abnormal **ER–mitochondrial Ca²⁺ flux** contributes to organelle swelling and vacuole formation.

- **Mitochondrial dysfunction**: loss of mitochondrial homeostasis, swelling, and metabolic stress are common, though paraptosis is typically **caspase-independent**.

- **Proteasome/ubiquitin–proteasome system inhibition**: impaired protein degradation can cause accumulation of misfolded proteins, ER stress, and paraptotic morphology.

- **IGF-1 receptor–related signaling**: classic descriptions of paraptosis linked it to **IGF-1R activation**, with modulation by proteins such as **AIP1/Alix**.

Mechanistically, paraptosis is usually characterized by **caspase-independent cell death**, extensive **ER and/or mitochondrial swelling**, and large-scale **cytoplasmic vacuolization**, often driven by **MAPK activation, ROS, ER stress, and disrupted proteostasis**.

### RAG answer

The pathway most frequently associated with paraptosis is the MAPK axis, particularly MEK/ERK and JNK signaling. The retrieved reviews describe paraptosis as caspase-independent and repeatedly emphasize MAPK activation as essential or primary for paraptosis-associated cytoplasmic vacuolization, often involving ER and/or mitochondrial swelling [PMC10308048:sec15:chunk0].
A common upstream trigger is IGF1R activation, which can engage MAPK/ERK and JNK pathways to induce paraptosis; inhibition of MEK-2 or JNK-1 suppresses IGF-IR-induced paraptosis in the cited 293T-cell studies [PMC11546839:sec12:chunk0]. Relatedly, endogenous regulators such as AIP1/Alix inhibit paraptosis by dampening MAPK activity, reinforcing MAPK as a core signaling node rather than a bystander [PMC10308048:sec15:chunk0; PMC11533606:sec10:chunk0].
Several recurrent stress-linked modules converge on this MAPK-centered phenotype: ROS generation, Ca²⁺ signaling, proteasome inhibition/ER stress, and ion-channel perturbation are repeatedly listed as paraptosis-inducing mechanisms [PMC12985128:sec2:chunk0; PMC10308048:sec15:chunk0]. Mechanistically, MAPK activation can promote nascent protein synthesis and misfolded-protein burden, leading to ER stress and vacuolization; in IL-1β-treated chondrocytes, MEK inhibition reduced ER dilation, PERK/CHOP activation, vacuolization, and cell death [PMC12056802:sec12:chunk0].
Other pathways are reported but appear more context-specific in the retrieved material. PI3K/AKT is linked to Zika virus-associated paraptosis-like death and iodine-125 radiation-induced paraptosis in colorectal cancer cells, while PLC–IP3R–Ca²⁺–PKCα signaling can activate MAPK downstream of GPCR stimulation [PMC9678488:sec0:chunk1; PMC11533606:sec10:chunk0]. Thus, the most recurrent association is MAPK/ERK/JNK signaling, with IGF1R, ROS, Ca²⁺ flux, ER stress/proteasome inhibition, and PI3K/AKT acting as upstream or context-dependent modules.

---

## Q21: What is the role of paraptosis in Alzheimer's disease?

- Expected group: LOW (RAG should learn to say "unknown")
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4475
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What is the role of paraptosis in Alzheimer's disease?

### GPT answer

Paraptosis is a **caspase-independent programmed cell death pathway** that may contribute to neuronal injury in Alzheimer’s disease, but its exact importance in human AD is still uncertain.

Mechanistically, AD-related stressors—especially **amyloid-β accumulation**—can trigger **paraptosis-like neuronal death** characterized by:

- **Extensive cytoplasmic vacuolization**
- **Swelling of the endoplasmic reticulum and mitochondria**
- **ER stress and disturbed protein handling**
- **Calcium dysregulation**
- **Oxidative stress and mitochondrial dysfunction**
- Activation of stress signaling pathways such as **MAPK/JNK/ERK**

Unlike apoptosis, paraptosis generally occurs **without caspase activation or classical apoptotic nuclear fragmentation**. In AD models, this pathway is thought to represent an alternative route by which neurons die when amyloid-β, proteotoxic stress, and organelle dysfunction overwhelm cellular repair systems.

So, paraptosis may be a **contributor to neurodegeneration in Alzheimer’s disease**, particularly through amyloid-β–induced ER/mitochondrial stress, but it is not yet as well established as apoptosis, necroptosis, autophagy-related dysfunction, or inflammatory mechanisms in AD.

### RAG answer

Paraptosis may contribute to Alzheimer’s disease–related neurodegeneration, but the retrieved evidence is limited to a mouse-model observation rather than definitive human causal evidence. In that model, neurodegeneration was associated with increased cell death resembling both paraptosis and autophagy [PMC11546839:sec17:chunk0].
Mechanistically, the relevant AD model involved overexpression of the Δ40 isoform of p53 together with a humanized amyloid precursor protein, which was linked to enhanced IGF-1R signaling and increased MAPK and JNK phosphorylation—features described as consistent with the original paraptosis pathway [PMC11546839:sec17:chunk0]. This fits the broader definition of paraptosis as a non-apoptotic programmed cell death mode characterized by cytoplasmic vacuolization, ER/mitochondrial swelling, and lack of caspase activation, rather than chromatin condensation or apoptotic body formation [PMC11533606:abstract:chunk0; PMC11533606:sec0:chunk0].
Thus, in Alzheimer’s disease, paraptosis is best viewed from these nodes as a candidate non-apoptotic neuronal death mechanism that may operate alongside autophagy, potentially downstream of IGF-1R–MAPK/JNK signaling in an APP/p53-context model [PMC11546839:sec17:chunk0]. However, evidence insufficient to conclude that paraptosis is a proven driver of human Alzheimer’s disease pathology or a validated therapeutic target in AD.

---

## Q22: What is the role of paraptosis in Parkinson's disease?

- Expected group: LOW (RAG should learn to say "unknown")
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4362
- Coverage: 0.5000
- Evidence count: 8
- Normalized retrieval query: What is the role of paraptosis in Parkinson's disease?

### GPT answer

Paraptosis may contribute to dopaminergic neuron loss in Parkinson’s disease, but its role is less well established than apoptosis, ferroptosis, necroptosis, or autophagy-related death.

Mechanistically, paraptosis is a caspase-independent programmed cell death characterized by:

- Extensive cytoplasmic vacuolization
- Swelling/dilation of endoplasmic reticulum and mitochondria
- Mitochondrial dysfunction and ROS production
- ER stress and unfolded protein response activation
- Impaired proteasomal/protein quality-control systems
- Often MAPK/JNK-related stress signaling
- Little or no classic apoptotic nuclear fragmentation

In Parkinson’s disease, these features overlap with major pathogenic processes: α-synuclein accumulation, mitochondrial complex I dysfunction, oxidative stress, calcium dysregulation, and ER/proteostasis stress. In experimental PD models, such stressors can produce paraptosis-like degeneration of dopaminergic neurons, suggesting paraptosis could be one route by which substantia nigra neurons die when protein folding and mitochondrial homeostasis fail.

However, direct evidence that paraptosis is a dominant mechanism in human Parkinson’s disease is still limited. It is best viewed as a possible contributing, caspase-independent death pathway that may interact with mitochondrial dysfunction, ER stress, and α-synuclein proteotoxicity rather than as the central established mechanism of PD neurodegeneration.

### RAG answer

Evidence insufficient to define a specific role of paraptosis in Parkinson’s disease from the retrieved nodes. None of the provided sources directly discuss Parkinson’s disease, dopaminergic neurons, α-synuclein, substantia nigra pathology, or PD models in relation to paraptosis.
What can be supported is that paraptosis is a regulated, non-apoptotic cell-death mode characterized by cytoplasmic vacuolization, ER dilation/swelling, mitochondrial swelling/dysfunction, and lack of caspase activation or classic apoptotic nuclear morphology [PMC11546839:sec30:chunk0; PMC11533606:abstract:chunk0]. Mechanistically, the retrieved literature links paraptosis to cellular stressors such as ER stress, oxidative damage, proteostasis disruption, and mitochondrial dysfunction, with MAPK signaling also implicated [PMC11546839:sec30:chunk0; PMC7941236:sec5:chunk0].
In the CNS/neurodegeneration context, the evidence is only indirect: one review notes that paraptosis has been considered relevant to neurodegenerative disease broadly and cites observations in Alzheimer’s disease and neuronal death models, including IGF-1R/p44-associated neuronal death with paraptosis/autophagy features [PMC11546839:sec30:chunk0; PMC7941236:sec5:chunk0]. However, these data do not establish that paraptosis contributes to Parkinson’s disease pathogenesis or progression.
Thus, based on the retrieved evidence, paraptosis can only be described as a stress-linked, non-apoptotic cell-death mechanism that could be conceptually relevant to neurodegeneration; its specific role in Parkinson’s disease remains unsupported here.

---

## Q23: Does paraptosis regulate circadian rhythm?

- Expected group: LOW (RAG should learn to say "unknown")
- Retrieval strength: MEDIUM
- Evidence diversity: MEDIUM
- Top1 score: 0.6400
- Top5 avg score: 0.5453
- Coverage: 0.3333
- Evidence count: 8
- Normalized retrieval query: Does paraptosis regulate circadian rhythm?

### GPT answer

No—there is no well-established evidence that **paraptosis directly regulates circadian rhythm**.

Mechanistically:

- **Circadian rhythm** is mainly controlled by transcription–translation feedback loops involving **CLOCK, BMAL1, PER, CRY, REV-ERB, and ROR**.
- **Paraptosis** is a form of programmed cell death characterized by **cytoplasmic vacuolization**, **ER/mitochondrial swelling**, proteostasis stress, and often **MAPK/ERK or JNK signaling**.
- These pathways can overlap indirectly: ER stress, ROS, calcium signaling, and MAPK activity can influence clock gene expression.
- However, paraptosis itself is not considered a core circadian regulatory mechanism.

So, paraptosis may **indirectly disturb circadian rhythms** if it damages or kills clock-regulating cells, but it is not known to physiologically regulate circadian timing.

### RAG answer

Evidence insufficient. The retrieved literature supports that paraptosis is a regulated cell-death program driven by proteostasis disruption, ER stress/UPR, ROS generation, mitochondrial/ER swelling, cytoplasmic vacuolization, and CDK7/CDK9–RNAPII-dependent stress transcription [PMC12221825:sec0:chunk0; PMC11163730:abstract:chunk0; PMC11163730:sec6:chunk0]. However, none of the retrieved nodes provides evidence that paraptosis regulates circadian rhythm, circadian clock genes, or rhythmic cellular timing.
Mechanistically, the available evidence points to a trigger → stress pathway → death phenotype sequence: paraptosis-inducing agents provoke ROS and proteotoxic/ER stress, activate UPR/HSP/redox-homeostasis programs, engage CDK7/CDK9–Rpb1 transcriptional activation, and culminate in vacuolization and cell death [PMC11163730:sec2:chunk0; PMC11163730:sec3:chunk0; PMC11533606:sec9:chunk1]. That mechanism could, in principle, intersect with pathways that also influence circadian biology, such as redox state or transcriptional regulation, but such an intersection is not demonstrated in the retrieved evidence.

---

## Q24: What is the relationship between paraptosis and aging?

- Expected group: LOW (RAG should learn to say "unknown")
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4850
- Coverage: 0.0000
- Evidence count: 8
- Normalized retrieval query: What is the relationship between paraptosis and aging?

### GPT answer

Paraptosis is a form of regulated, non-apoptotic cell death characterized mainly by extensive cytoplasmic vacuolization from swelling of the endoplasmic reticulum and/or mitochondria, often linked to proteotoxic stress, ER stress, mitochondrial dysfunction, ROS, and MAPK signaling.

Its relationship with aging is mostly indirect and not as well established as apoptosis, necroptosis, autophagy, or cellular senescence.

Mechanistically, aging can promote conditions that favor paraptosis-like death:

- **Proteostasis decline:** aged cells have reduced proteasome/autophagy capacity, increasing misfolded protein stress.
- **ER stress:** chronic unfolded protein response activation can drive ER dilation and vacuolization.
- **Mitochondrial dysfunction:** aging-associated mitochondrial damage and ROS production can sensitize cells to paraptotic pathways.
- **Oxidative stress:** elevated ROS can amplify MAPK/JNK/p38 signaling involved in paraptosis-like death.
- **Impaired stress recovery:** aged cells may be less able to resolve sublethal stress, shifting toward cell death.

Potentially, excessive paraptosis could contribute to **age-related tissue degeneration**, especially in post-mitotic tissues such as neurons or muscle, if stressed cells undergo paraptotic death. Conversely, inducing paraptosis may be useful for eliminating damaged, apoptosis-resistant, or cancerous cells, which become more common with aging.

In short: **aging creates cellular stress states that may predispose cells to paraptosis, but paraptosis is not yet considered a central or well-defined driver of aging.** Its role in aging biology remains plausible but incompletely proven.

### RAG answer

Evidence insufficient to define a direct relationship between paraptosis and aging from the retrieved nodes.
The available material characterizes paraptosis as a programmed, non-apoptotic cell death mode marked by ER and/or mitochondrial swelling, cytoplasmic vacuolization, lack of DNA fragmentation, and caspase independence [PMC12985128:sec2:chunk0; PMC7873879:abstract:chunk0]. Mechanistically, it is linked to cellular stress pathways including MAPK activation, ROS generation, calcium dysregulation at the ER–mitochondria axis, proteostasis disturbance, ER stress, and autophagy-related changes [PMC12985128:sec2:chunk0; PMC7873879:abstract:chunk0; PMC12985128:sec17:chunk0].
However, none of the retrieved nodes directly discuss aging, senescence, lifespan, age-related tissue decline, or organismal aging phenotypes. The closest relevant overlap is that paraptosis is reported in neurodegenerative diseases and can occur as a response to cellular stressors such as oxidative stress, heat shock, toxic compounds, and organelle dysfunction [PMC12985128:sec2:chunk0; PMC11546839:sec21:chunk0]. These are biologically adjacent to aging research, but the retrieved evidence does not support a claim that paraptosis drives aging, protects against aging, or is altered during aging.
Thus, based strictly on these nodes, paraptosis can be described as a stress-associated non-apoptotic death pathway with relevance to diseases often studied in aging contexts, but its specific relationship to aging remains unsupported here.

---

## Q25: How does paraptosis influence embryonic development?

- Expected group: LOW (RAG should learn to say "unknown")
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.5027
- Coverage: 0.6667
- Evidence count: 8
- Normalized retrieval query: How does paraptosis influence embryonic development?

### GPT answer

Paraptosis likely influences embryonic development by acting as a **non-apoptotic programmed cell death mechanism** that helps regulate tissue remodeling and cell number.

Mechanistically, paraptosis is characterized by:

- **Caspase-independent cell death**
- **Extensive cytoplasmic vacuolization**
- Swelling of the **endoplasmic reticulum and mitochondria**
- Disruption of **protein homeostasis**
- Often involvement of **ER stress, calcium imbalance, ROS, and MAPK/JNK signaling**

During embryonic development, paraptosis-like death could help remove inappropriate, damaged, or excess cells when classical apoptosis is not the dominant pathway. By doing so, it may contribute to **morphogenesis, organ shaping, and developmental quality control**.

However, compared with apoptosis, the role of paraptosis in embryogenesis is **less well established**, and much of its developmental significance remains uncertain. Excessive or poorly regulated paraptosis could theoretically impair tissue formation and contribute to developmental defects.

### RAG answer

Paraptosis may influence embryonic development as a non-apoptotic programmed cell-death route that helps remove or remodel cells during tissue differentiation and morphogenesis, but the retrieved evidence is insufficient to define specific embryonic stages, tissues, or developmental phenotypes.
Mechanistically, paraptosis differs from apoptosis: it is caspase-independent, lacks DNA fragmentation/chromatin condensation/apoptotic bodies, and is marked by ER and mitochondrial swelling with large cytoplasmic vacuoles [PMC11533606:sec0:chunk0; PMC10474147:sec13:chunk0]. Proposed upstream triggers include IGF-IR-related signaling with MEK-2/JNK pathway involvement, proteostasis stress, ion imbalance, ER stress, and ER–mitochondrial Ca²⁺ flux, which together can produce organelle dilation and cell death [PMC10474147:sec13:chunk0].
In developmental contexts, paraptosis is described as being implicated in normal tissue differentiation and remodeling, and paraptosis-like death has been reported in follicular atresia during ovarian development, where granulosa cells showed dilated ER but lacked TUNEL positivity and active caspase-3—supporting a non-apoptotic mode of cell elimination [PMC11546839:sec16:chunk0]. More broadly, programmed cell death is stated to regulate tissue development, differentiation, and homeostasis, and paraptosis is considered one such programmed death modality [PMC11533606:sec0:chunk0; PMC11606808:sec1:chunk0].
Thus, the most defensible interpretation is that paraptosis could contribute to embryonic development by selectively eliminating cells through ER/mitochondrial stress-associated, caspase-independent death during tissue remodeling. However, direct evidence in the retrieved nodes for how paraptosis shapes embryogenesis is limited; detailed developmental roles remain evidence insufficient.

---

## Q26: What is the relationship between paraptosis and exercise adaptation?

- Expected group: LOW (RAG should learn to say "unknown")
- Retrieval strength: MEDIUM
- Evidence diversity: MEDIUM
- Top1 score: 0.6400
- Top5 avg score: 0.5572
- Coverage: 0.0000
- Evidence count: 8
- Normalized retrieval query: What is the relationship between paraptosis and exercise adaptation?

### GPT answer

Paraptosis is **not considered a normal or central mechanism of exercise adaptation**.

Mechanistically, there is some overlap in stress signaling:

- **Exercise adaptation** depends on controlled, transient stress signals: ROS, Ca²⁺ flux, AMPK/p38 MAPK activation, ER/mitochondrial stress responses, autophagy, and PGC-1α–driven mitochondrial biogenesis.
- **Paraptosis** is a non-apoptotic cell-death program marked by large cytoplasmic vacuoles, ER/mitochondrial swelling, proteostasis failure, oxidative stress, and MAPK/ER-stress signaling.

So the relationship is mainly this:

**Moderate exercise activates mild ER/mitochondrial stress that promotes adaptation and survival, whereas excessive or unresolved stress could theoretically shift cells toward maladaptive injury pathways, including paraptosis-like death.**

In skeletal muscle, beneficial training adaptation is more strongly linked to **autophagy, mitochondrial remodeling, antioxidant upregulation, inflammation resolution, and satellite-cell responses**, not paraptosis. If paraptosis occurs, it would likely reflect **pathological over-stress or damage**, not productive adaptation.

### RAG answer

Evidence insufficient to establish a relationship between paraptosis and exercise adaptation from the retrieved nodes.
The available material discusses paraptosis mainly in cancer contexts: it is described as a caspase-independent, non-apoptotic cell death mode characterized by cytoplasmic vacuolization and ER/mitochondrial dilation, often linked to MAPK signaling and ER-stress conditions [PMC12985128:sec19:chunk0; PMC12985128:sec3:chunk0]. It also emphasizes crosstalk with autophagy, where autophagy can act cytoprotectively by clearing damaged organelles and misfolded proteins, while paraptosis may emerge when proteostasis/ER stress is unresolved or autophagic flux is disrupted [PMC12985128:sec16:chunk0; PMC12985128:sec20:chunk0].
However, none of the retrieved nodes address exercise, skeletal muscle adaptation, endurance or resistance training responses, mitochondrial biogenesis, hormesis, or training-induced remodeling. Therefore, the retrieved evidence does not support a specific mechanistic claim that paraptosis contributes to—or is regulated during—exercise adaptation.

---

## Q27: Does paraptosis affect weather-related stress responses?

- Expected group: LOW (RAG should learn to say "unknown")
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4081
- Coverage: 0.8000
- Evidence count: 8
- Normalized retrieval query: Does paraptosis affect weather-related stress responses?

### GPT answer

Not directly, in the usual sense.

**Paraptosis** is a form of regulated cell death marked by **ER/mitochondrial swelling, cytoplasmic vacuolization, ROS/ER stress, calcium disturbance, and often MAPK signaling**, typically **caspase-independent**.

Weather-related stresses—such as **heat, cold, drought/osmotic stress, UV exposure, hypoxia, or oxidative stress**—can activate cellular stress pathways. If severe, these stresses may **trigger paraptosis-like cell death** in affected cells.

Mechanistically:

- **Heat/UV/drought-like osmotic stress → ROS and protein misfolding**
- **ROS/ER stress → calcium imbalance and mitochondrial dysfunction**
- **MAPK activation and organelle swelling → paraptosis-like death**

So, **paraptosis does not regulate weather-related stress responses as a primary adaptive pathway**, but **weather-related cellular stress can induce paraptosis-like death**, contributing to tissue injury when stress is excessive. In plants, “paraptosis” is not usually the standard term; researchers more often describe related processes as **programmed cell death or vacuolar/necrosis-like cell death** under abiotic stress.

### RAG answer

Evidence insufficient to conclude that paraptosis regulates “weather-related stress responses” as a defined physiological category. The retrieved literature supports a narrower point: paraptosis can be induced by cellular stressors that may overlap with environmental/weather-associated insults, especially heat shock and oxidative stress, but it does not show that paraptosis controls organism-level responses to weather, climate, temperature exposure, humidity, or related environmental adaptation [PMC11546839:sec21:chunk0].
Mechanistically, stress-induced paraptosis appears to proceed through oxidative and proteotoxic injury: ROS generation, impaired proteasome activity, ER stress/UPR activation, mitochondrial dysfunction, and Ca²⁺ imbalance can reinforce one another, producing ER/mitochondrial dilation, cytoplasmic vacuolization, ATP depletion, and ultimately cell death [PMC11533606:sec9:chunk0; PMC11533606:sec9:chunk1; PMC7873879:abstract:chunk0]. ROS-triggered BK-channel activation and ER stress-mediated misfolded protein accumulation are also described as routes into paraptotic swelling and vacuolization [PMC11606808:sec2:chunk0].
Thus, if “weather-related stress” means heat or oxidative cellular stress, paraptosis could plausibly participate by eliminating damaged cells under those stress conditions. But the retrieved evidence does not demonstrate a specific role for paraptosis in weather-related stress responses beyond these general cellular stress pathways [PMC11546839:sec21:chunk0].

---

## Q28: What is the role of paraptosis in plant immunity?

- Expected group: LOW (RAG should learn to say "unknown")
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.5872
- Coverage: 0.5000
- Evidence count: 8
- Normalized retrieval query: What is the role of paraptosis in plant immunity?

### GPT answer

Paraptosis is not a well-established, canonical cell-death pathway in plants in the same way it is described in animal cells. However, **paraptosis-like programmed cell death** has been proposed to contribute to plant immunity.

Mechanistically, its possible role is to:

- **Promote localized cell death during the hypersensitive response** to restrict biotrophic pathogen spread.
- Involve **large cytoplasmic/vacuolar swelling**, often linked to **ER stress**, disrupted vesicle trafficking, and organelle dysfunction.
- Act independently of classical apoptotic markers such as caspases, which plants do not possess in the animal sense.
- Be associated with immune signals such as **ROS accumulation, calcium fluxes, MAPK activation, and stress-response pathways**.
- Potentially help amplify defense signaling and containment of infected tissue.

So, in plant immunity, paraptosis-like death may function as a **non-apoptotic programmed cell death mechanism that supports pathogen restriction**, but its exact molecular definition and importance in plants remain uncertain compared with better-characterized processes like hypersensitive-response cell death and autophagy-associated cell death.

### RAG answer

Evidence insufficient to define a role for paraptosis in plant immunity.
The retrieved literature discusses paraptosis mainly as a non-apoptotic programmed cell death mode characterized by cytoplasmic vacuolization, ER/mitochondrial damage or swelling, caspase independence, and often MAPK-associated signaling, but these descriptions are in cancer or mammalian cellular-stress contexts rather than plant immune responses [PMC10308048:abstract:chunk0].
The immune-related evidence provided concerns tumor immunity: paraptosis can increase tumor immunogenicity, promote danger-signal/DAMP-associated responses, recruit or activate immune cells, and enhance antitumor T-cell or macrophage-mediated effects [PMC11606808:sec3:chunk1; PMC11533606:sec21:chunk0]. However, these findings cannot be extrapolated to plant immunity from the retrieved nodes.
Thus, based only on the supplied evidence, paraptosis may be an immunogenic cell-death process in cancer models, but its occurrence, mechanisms, or functional significance in plant immunity are not supported here.

---

## Q29: Can programmed vacuolar cell death overcome drug resistance?

- Expected group: Query Rewrite Stress Test
- Retrieval strength: MEDIUM
- Evidence diversity: MEDIUM
- Top1 score: 0.7148
- Top5 avg score: 0.5985
- Coverage: 0.8571
- Evidence count: 8
- Normalized retrieval query: Can programmed vacuolar cell death overcome drug resistance?

### GPT answer

Yes—**in principle, programmed vacuolar cell death can help overcome some forms of drug resistance**, especially when resistance is due to failure of apoptosis.

Mechanistically, many resistant cancer cells evade therapy by blocking apoptotic pathways, such as p53 signaling, caspase activation, or mitochondrial outer membrane permeabilization. Vacuolar cell death is often **caspase-independent** and involves massive cytoplasmic vacuolization, disruption of endosomal/lysosomal or ER-derived compartments, impaired autophagic flux, lysosomal membrane permeabilization, cathepsin release, and eventual metabolic or membrane collapse. Because it does not rely primarily on canonical apoptosis, it may kill cells that are apoptosis-resistant.

However, it would **not overcome all drug resistance**. If resistance is caused by poor drug uptake, drug efflux pumps, enhanced detoxification, or target mutation, a vacuolar-death-inducing agent may still fail unless it bypasses those mechanisms.

So the short answer is: **yes, potentially, but mainly for apoptosis-based resistance; it is not a universal solution and remains context-dependent.**

### RAG answer

Yes—if by “programmed vacuolar cell death” you mean paraptosis-like, vacuolation-associated programmed cell death, the retrieved evidence supports its potential to overcome anticancer drug resistance, especially resistance linked to apoptosis evasion. Paraptosis is caspase-independent and marked by cytoplasmic vacuolation with ER/mitochondrial swelling rather than apoptotic nuclear fragmentation, making it mechanistically distinct from apoptosis [PMC12839049:sec8:chunk0]. Because many resistant tumors evade apoptosis, activating non-apoptotic death programs such as paraptosis is presented as a strategy to bypass that resistance [PMC10792489:abstract:chunk0; PMC11533606:sec20:chunk0].
Mechanistically, paraptosis can be triggered by ER stress, Ca²⁺ overload, ROS, and MAPK/JNK-related signaling, leading to vacuole formation from ER/mitochondrial dilation and ultimately cell death [PMC12839049:sec8:chunk0]. In resistant cancer models, α-hederin induced paraptosis in 5-fluorouracil-resistant HT-29 colorectal cancer cells through the PLCβ3–IP3R–Ca²⁺–PKCα pathway, while elaiophylin promoted cytoplasmic vacuolization and paraptosis by activating the SHP2–SOS1 pathway and hyperactivating MAPK signaling [PMC11533606:sec20:chunk0].
There is also evidence that copper-containing agents can kill resistant cancer cells through paraptosis: copper complexes inhibited cisplatin-resistant ovarian adenocarcinoma and doxorubicin-resistant colon carcinoma cell lines, accompanied by G2/M arrest, mitochondrial membrane potential loss, ROS generation, and paraptotic death [PMC11533606:sec20:chunk0]. More broadly, paraptosis induction via nanomedicines, copper complexes, or shikonin is described as promising in apoptosis-resistant cancers, although biomarker development and pathway overlap with autophagy/cuproptosis remain challenges [PMC12839049:sec8:chunk0].
So, the answer is yes in principle and in preclinical cancer contexts, but the evidence here supports “promising strategy” rather than established clinical proof.

---

## Q30: How does ER swelling lead to non-apoptotic vacuolating cell death?

- Expected group: Query Rewrite Stress Test
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4767
- Coverage: 0.8571
- Evidence count: 8
- Normalized retrieval query: How does ER swelling lead to non-apoptotic vacuolating cell death?

### GPT answer

ER swelling can cause a form of non-apoptotic vacuolating cell death often resembling **paraptosis**.

Mechanistically:

- **ER stress or proteostasis failure** causes accumulation of misfolded/unfolded proteins in the ER lumen.
- This increases **osmotic load** inside the ER, drawing in water and causing **ER cisternae to dilate**.
- Disturbed **Ca²⁺ handling**, ion fluxes, and impaired ER-associated degradation can further drive ER expansion.
- The swollen ER forms large **cytoplasmic vacuoles** derived from ER membranes, not autophagosomes or lysosomes.
- Persistent ER dilation disrupts **protein folding, lipid synthesis, Ca²⁺ homeostasis, and ER–mitochondria communication**.
- Mitochondrial dysfunction, ATP depletion, ROS production, and unresolved unfolded protein response then push the cell toward death.
- Unlike apoptosis, this process usually lacks **caspase activation, DNA fragmentation, nuclear condensation, and apoptotic bodies**.
- The terminal event is often progressive organelle dysfunction and eventual **loss of cellular integrity**, rather than an ordered apoptotic program.

So, ER swelling kills cells by producing massive vacuolization and catastrophic failure of ER-dependent homeostasis, leading to a non-apoptotic, vacuolating cell death phenotype.

### RAG answer

ER swelling drives non-apoptotic vacuolating cell death mainly through paraptosis: unresolved ER stress causes luminal protein/ion imbalance, osmotic water influx, ER dilation into cytoplasmic vacuoles, and secondary mitochondrial swelling via ER–mitochondrial Ca²⁺ transfer, producing extensive vacuolization without the canonical apoptotic morphology or caspase-dependent program [PMC12839049:sec8:chunk0; PMC11546839:sec10:chunk0].
Mechanistically, impaired proteostasis—such as proteasome inhibition or other disruptions of protein folding—allows misfolded proteins to accumulate in the ER lumen. This increases osmotic pressure, draws water from the cytoplasm, and expands the ER; ER-derived vacuoles can retain ribosome-studded membranes, supporting their ER origin [PMC11420017:sec17:chunk0; PMC11546839:sec10:chunk0]. Thus, ER “swelling” is not merely a marker but a physical driver of vacuole formation.
The swollen/stressed ER also releases Ca²⁺ to mitochondria through the ER–mitochondrial axis. Mitochondrial Ca²⁺ overload can impair Ca²⁺ extrusion, collapse mitochondrial membrane potential, promote proton accumulation, and cause mitochondrial swelling, adding to the vacuolated phenotype [PMC12284444:sec20:chunk0; PMC11546839:sec10:chunk0]. ROS and ion-homeostasis defects can amplify both ER stress and Ca²⁺ overload, reinforcing the cycle of organelle dilation [PMC12839049:sec8:chunk0; PMC11546839:sec10:chunk0].
The resulting death is considered non-apoptotic because it is characterized by cytoplasmic vacuolization and ER/mitochondrial swelling while lacking typical apoptotic features such as nuclear fragmentation, DNA breaks, and cysteinyl-aspartate protease activation [PMC12839049:sec8:chunk0; PMC11420017:sec17:chunk0]. In cancer cells, this paraptotic route is therefore discussed as a way to kill cells that resist apoptosis, although biomarkers and pathway boundaries remain challenging because of overlap with other stress responses [PMC12839049:sec8:chunk0].

---

## Q31: What role does PI4KB play in paraptosis-related breast cancer prognosis models?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Gene-specific and prognostic models
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9978
- Top5 avg score: 0.7756
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What role does PI4KB play in paraptosis-related breast cancer prognosis models?

### GPT answer

PI4KB is typically treated as a **paraptosis-related prognostic risk gene** in breast cancer models.

Mechanistically, PI4KB encodes **phosphatidylinositol 4-kinase IIIβ**, which generates **PI4P** mainly at the Golgi/trans-Golgi network. This affects:

- Golgi/ER membrane trafficking  
- phosphoinositide signaling  
- vesicle formation and organelle homeostasis  
- cellular stress responses that can intersect with **paraptosis-like vacuolization** of ER/mitochondria

In prognosis signatures, higher PI4KB expression is generally interpreted as contributing to a **higher-risk tumor phenotype**, often associated with worse survival, greater tumor cell survival capacity, and altered stress-response signaling.

So, in these models, PI4KB is less a proven direct “executor” of paraptosis and more a **biomarker linking membrane/phosphoinositide signaling to paraptosis-related breast cancer prognosis**.

### RAG answer

PI4KB functions as an oncogenic, prognostically relevant component of a paraptosis-related breast cancer risk model, rather than just a passive correlate. In the PRRS model, PI4KB was one of six genes retained after Cox/LASSO/multivariate Cox selection for constructing the paraptosis-related risk score, and it showed relatively high copy-number amplification among the model genes [PMC12685561:sec18:chunk0].
Mechanistically, the study prioritized PI4KB because it had strong oncogenic and prognostic relevance and was linked to the ER stress–AKT/MAPK axis implicated in paraptosis; unlike HSPB8 and USP10, its role in paraptosis-related pathways had been relatively unexplored, making it a novel validation candidate [PMC12685561:sec24:chunk0]. In the broader PRRS framework, lower PRRS was associated with better prognosis, lower tumor purity, and greater immune infiltration, indicating that paraptosis-related gene expression—including PI4KB as a model gene—helps stratify both survival risk and tumor immune contexture [PMC12685561:abstract:chunk0].
Functionally, PI4KB was highly expressed in breast cancer, and PI4KB knockdown suppressed breast cancer cell proliferation, colony formation, migration, and invasion in vitro [PMC12685561:sec24:chunk0; PMC12685561:abstract:chunk0]. Thus, within paraptosis-related breast cancer prognosis modeling, PI4KB serves as a high-risk/oncogenic biomarker candidate with experimental support, and the authors propose it as a promising prognostic biomarker and therapeutic target [PMC12685561:sec26:chunk0].

---

## Q32: How is PI4KB linked to the ER stress-AKT/MAPK axis in paraptosis-related breast cancer?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Gene-specific and prognostic models
- Retrieval strength: HIGH
- Evidence diversity: HIGH
- Top1 score: 1.0000
- Top5 avg score: 0.4518
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How is PI4KB linked to the ER stress-AKT/MAPK axis in paraptosis-related breast cancer?

### GPT answer

PI4KB links to the ER stress–AKT/MAPK axis as an upstream phosphoinositide regulator of membrane/ER–Golgi homeostasis and survival signaling in breast cancer cells.

Mechanistically:

- **PI4KB produces PI4P**, supporting Golgi/ER trafficking and lipid signaling.
- When **PI4KB is inhibited or knocked down**, PI4P-dependent trafficking is disturbed, causing **ER stress** and ER dilation/vacuolization.
- ER stress activates unfolded-protein-response markers such as **GRP78/BiP, PERK–eIF2α–ATF4, and CHOP**.
- This stress state perturbs survival pathways: typically **AKT signaling is suppressed**, while stress MAPK arms such as **ERK/JNK/p38** may become aberrantly activated.
- The result is **paraptosis-like death**: extensive cytoplasmic vacuoles from swollen ER/mitochondria, little or no caspase dependence, and resistance to classic apoptosis blockade.

So, in paraptosis-related breast cancer, **PI4KB appears to act as a pro-survival node; loss of PI4KB triggers ER stress, rewires AKT/MAPK signaling, and promotes caspase-independent paraptotic cell death.**

### RAG answer

PI4KB is linked to the ER stress–AKT/MAPK axis in paraptosis-related breast cancer mainly as a newly prioritized oncogenic/paraptosis-related biomarker, not yet as a fully mechanistically dissected effector. In the breast cancer PRRS model, PI4KB was selected for validation because it combined strong prognostic/oncogenic relevance with a proposed mechanistic connection to the ER stress–AKT/MAPK axis involved in paraptosis [PMC12685561:sec24:chunk0].
Functionally, PI4KB appears to support malignant breast cancer phenotypes: it is reported as highly expressed in breast cancer, and PI4KB knockdown suppressed proliferation, colony formation, migration, and invasion in vitro [PMC12685561:sec24:chunk0; PMC12685561:abstract:chunk0]. This places PI4KB on the pro-tumor side of the paraptosis-related risk framework, where paraptosis-related genes stratify prognosis, immune features, and therapeutic sensitivity [PMC12685561:abstract:chunk0; PMC12685561:sec26:chunk0].
Mechanistically, the “ER stress” part is consistent with the broader paraptosis biology in breast cancer: paraptosis inducers can act through ER stress, calcium-homeostasis disruption, ER/mitochondrial dilation, and UPR/ISR effectors such as PERK–eIF2α, ATF4, and CHOP [PMC12685561:sec0:chunk1; PMC11533606:sec7:chunk1]. The AKT connection is supported more generally by paraptosis studies showing that proteotoxic stress activates ISR signaling, ATF4, and DDIT4, which is associated with mTORC2/AKT activation during paraptosis [PMC10787777:sec5:chunk0].
However, the retrieved evidence does not define the exact biochemical route by which PI4KB regulates ER stress, AKT, or MAPK signaling in breast cancer cells. Thus, the best-supported interpretation is: PI4KB is an oncogenic breast cancer factor nominated within a paraptosis-related model as connected to the ER stress–AKT/MAPK axis, and PI4KB depletion suppresses aggressive phenotypes, but the direct PI4KB → ER stress → AKT/MAPK → paraptosis mechanism remains evidence insufficient from the available nodes.

---

## Q33: What happens to breast cancer cells when PI4KB is knocked down?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Gene-specific and prognostic models
- Retrieval strength: HIGH
- Evidence diversity: MEDIUM
- Top1 score: 1.0000
- Top5 avg score: 0.5378
- Coverage: 0.6250
- Evidence count: 8
- Normalized retrieval query: What happens to breast cancer cells when PI4KB is knocked down?

### GPT answer

When **PI4KB is knocked down in breast cancer cells**, the cells generally show **impaired tumor-promoting behavior**:

- **Reduced proliferation and colony formation**
- **Decreased migration and invasion**
- **Cell-cycle arrest and/or increased apoptosis**
- Mechanistically, loss of PI4KB lowers **PI4P-dependent membrane signaling/trafficking** and can reduce downstream survival pathways such as **PI3K–AKT signaling**

Overall, PI4KB knockdown makes breast cancer cells less viable, less invasive, and less tumorigenic.

### RAG answer

When PI4KB is knocked down in breast cancer cells, the cells show reduced malignant behavior: proliferation is suppressed, colony-forming capacity decreases, and invasion/migration are inhibited [PMC12685561:sec24:chunk0]. The abstract summarizes the same functional outcome, stating that PI4KB knockdown significantly suppressed breast cancer cell proliferation and migration [PMC12685561:abstract:chunk0].
Mechanistically, the retrieved study frames PI4KB as an oncogenic, prognosis-associated gene linked to the ER stress–AKT/MAPK axis in the context of paraptosis-related biology, but the experimental knockdown data mainly support a phenotype of impaired growth and motility rather than directly proving paraptotic cell death after PI4KB silencing [PMC12685561:sec24:chunk0]. Thus, PI4KB appears to support breast cancer progression, and its knockdown shifts cells toward a less proliferative and less invasive state.

---

## Q34: What does USP10 represent in paraptosis-related prognostic models?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Gene-specific and prognostic models
- Retrieval strength: HIGH
- Evidence diversity: MEDIUM
- Top1 score: 0.9293
- Top5 avg score: 0.6351
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What does USP10 represent in paraptosis-related prognostic models?

### GPT answer

USP10 represents **ubiquitin-specific peptidase/protease 10**, a **deubiquitinating enzyme** used as a gene variable in some **paraptosis-related prognostic risk models**.

Mechanistically, its inclusion suggests that **ubiquitin–proteasome/protein-homeostasis signaling** may be linked to paraptosis biology, because paraptosis involves proteotoxic stress, ER/mitochondrial swelling, and disrupted cellular stress responses. In a prognostic model, USP10 expression is therefore treated mainly as a **biomarker contributing to the calculated risk score**, not necessarily as definitive proof that USP10 directly executes paraptosis.

### RAG answer

USP10 represents a paraptosis-related prognostic signature gene—specifically, one of the six genes retained to construct a breast cancer paraptosis-related risk score (PRRS), not a universal component of all paraptosis prognostic models. In that BC model, USP10 entered the risk formula with a positive coefficient: risk score included “0.00585764541858519 × USP10,” implying higher USP10 expression contributes to a higher calculated PRRS when other genes are held constant [PMC12685561:sec19:chunk0].
Biologically, USP10 is a deubiquitinase that removes ubiquitin tags from target proteins, helping prevent their degradation and maintain protein homeostasis. It can bind and deubiquitinate beclin 1 to promote autophagy, and it has also been reported as expressed in malignant breast cancer cells during paraptosis, supporting its classification as a paraptotic regulator in this context [PMC12985128:sec14:chunk0].
In the breast cancer prognostic study, USP10 was among six key paraptosis-related genes selected after Cox/LASSO/multivariate modeling, and copy-number loss was noted for USP10 among those genes [PMC12685561:sec18:chunk0]. By contrast, the LUAD paraptosis-related model identified CDKN3, PEBP1, TNFRSF19, and PHB—not USP10—so the retrieved evidence supports USP10 mainly as a breast cancer PRRS component rather than a LUAD prognostic marker [PMC12928938:abstract:chunk0].

---

## Q35: Why is LCK included in a paraptosis-related breast cancer risk score?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Gene-specific and prognostic models
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9654
- Top5 avg score: 0.7578
- Coverage: 0.8750
- Evidence count: 8
- Normalized retrieval query: Why is LCK included in a paraptosis-related breast cancer risk score?

### GPT answer

LCK is likely included because it is a **prognostic, paraptosis-associated marker**, not because it is a canonical paraptosis execution gene.

Mechanistically:

- **LCK encodes a Src-family tyrosine kinase** central to T-cell receptor signaling.
- In bulk breast tumor data, high LCK expression usually reflects **T-cell/immune-cell infiltration** within the tumor microenvironment.
- Paraptosis-related signatures often capture pathways involving **MAPK signaling, ER stress, mitochondrial dysfunction, ROS, and immune response**. LCK-driven signaling can intersect with some of these pathways indirectly.
- Therefore, LCK may serve as a marker of an **immune-active tumor state** that is associated with altered susceptibility to non-apoptotic cell death programs and better or worse prognosis depending on the model coefficient.
- Its inclusion in a risk score usually means that statistical modeling found LCK expression to be **associated with survival/risk among paraptosis-related genes**, rather than proving that LCK directly induces paraptosis in breast cancer cells.

So, LCK is included mainly as an **immune/prognostic surrogate linked to paraptosis-associated biology**, especially tumor immune contexture, rather than as a direct paraptosis effector.

### RAG answer

LCK is included because, in this study, it survived the authors’ prognostic feature-selection pipeline for breast cancer paraptosis-related genes: it was among genes associated with overall survival in univariate Cox analysis, retained with a nonzero coefficient by LASSO, and then kept in the final six-gene multivariate Cox model used to construct the paraptosis-related risk score (PRRS) [PMC12685561:sec18:chunk0]. In that final PRRS formula, LCK carries a negative coefficient, meaning higher LCK expression contributes to a lower calculated risk score within this model [PMC12685561:sec19:chunk0].
The broader implication is that LCK is part of a six-gene PRRS—USP10, NT5C, HSPB8, LCK, PI4KB, and GPR153—that stratified breast cancer patients into prognostic groups, with low-risk patients showing better overall survival in TCGA and an external GEO validation cohort [PMC12685561:sec19:chunk0]. The study also reports that this PRRS relates to immune features: low PRRS was associated with favorable prognosis, reduced tumor purity, and enhanced immune infiltration [PMC12685561:abstract:chunk0].
Mechanistically, the retrieved evidence supports an immune/TME interpretation rather than a specific LCK-driven paraptosis mechanism. Differential genes between PRRS groups were enriched in cytokine–cytokine receptor interaction, T-cell regulation, PD1 expression, cell adhesion, and regulation of T-cell cytokine activity, suggesting that prognostic differences may reflect immune-response activity [PMC12685561:sec20:chunk0]. The authors further conclude that paraptosis-related genes, including LCK, correlate with prognosis, clinical features, and immune infiltration in breast cancer [PMC12685561:sec26:chunk0].
So, LCK is included not because the provided text proves that LCK directly induces paraptosis, but because its expression added independent prognostic value within a paraptosis-related gene signature and aligned with an immune microenvironment-associated risk phenotype. Evidence for a direct molecular LCK → paraptosis pathway is insufficient in the retrieved nodes.

---

## Q36: How does the paraptosis-related risk score (PRRS) predict breast cancer prognosis?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Gene-specific and prognostic models
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 1.0000
- Top5 avg score: 0.8503
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does the paraptosis-related risk score (PRRS) predict breast cancer prognosis?

### GPT answer

The paraptosis-related risk score (PRRS) predicts breast cancer prognosis by using the expression pattern of selected paraptosis-associated genes to stratify patients into risk groups.

Mechanistically and clinically:

- **High PRRS** generally indicates a tumor gene-expression profile linked to impaired or altered paraptosis-related cell death, greater stress tolerance, tumor progression, and a less favorable tumor microenvironment.
- Patients with a **high PRRS** are predicted to have **worse prognosis**, usually reflected by shorter overall survival or disease-free survival.
- Patients with a **low PRRS** are predicted to have **better prognosis**, with longer survival and often more favorable immune or therapeutic-response features.
- In prognostic models, PRRS is typically tested as an **independent risk factor** alongside age, stage, grade, and molecular subtype.
- It may also help identify patients more likely to benefit from certain treatments, though this depends on the specific gene signature and validation cohort.

In short: **a higher PRRS predicts poorer breast cancer outcomes, while a lower PRRS predicts better survival**, by capturing tumor biology related to paraptosis regulation, stress-response pathways, and aggressiveness.

### RAG answer

The PRRS predicts breast cancer prognosis by converting the expression of six paraptosis-related genes—USP10, NT5C, HSPB8, LCK, PI4KB, and GPR153—into a composite risk score that stratifies patients into high- and low-risk survival groups [PMC12685561:sec18:chunk0; PMC12685561:sec19:chunk0]. In the TCGA-BRCA training cohort, patients with low PRRS had significantly better overall survival than those with high PRRS, and the model showed time-dependent prognostic performance with AUCs of 0.74, 0.65, and 0.68 for 1-, 3-, and 5-year survival, respectively [PMC12685561:sec19:chunk0]. This prognostic separation was also externally validated in a GEO breast cancer cohort, where high-risk patients again had significantly worse survival than low-risk patients [PMC12685561:sec19:chunk0].
Mechanistically, PRRS appears to capture a paraptosis-linked immune microenvironment state. Low PRRS tumors had lower tumor purity but higher stromal and immune scores, with greater infiltration of immune populations including CD8+ T cells, CD4+ T cells, activated B cells, dendritic cells, M1 macrophages, and Tregs [PMC12685561:abstract:chunk0; PMC12685561:sec22:chunk0]. In contrast, high PRRS tumors showed reduced immune-cell infiltration and higher tumor purity, consistent with a more immune-depleted microenvironment that may contribute to poorer survival [PMC12685561:sec22:chunk0; PMC12685561:sec25:chunk1].
The score also has therapeutic implications: low-risk tumors showed higher expression of immune checkpoints, HLA-family genes, cytolysis-related activity, antigen-presentation features, and T-cell co-stimulatory/co-inhibitory signatures, suggesting a more immune-active phenotype and potentially greater sensitivity to immunotherapy [PMC12685561:sec22:chunk0; PMC12685561:sec25:chunk1]. Drug-sensitivity analyses further suggested that low-PRRS patients may be more sensitive to CDK4/6 inhibitors such as palbociclib and ribociclib, the PIK3CA-targeted drug alpelisib, and the estrogen receptor modulator epirubicin [PMC12685561:sec25:chunk1].
Thus, in breast cancer, a high PRRS predicts worse prognosis and an immune-poor, higher-purity tumor state, whereas a low PRRS predicts better overall survival, stronger immune infiltration/activation, and potentially more favorable responsiveness to selected therapies [PMC12685561:abstract:chunk0; PMC12685561:sec19:chunk0; PMC12685561:sec22:chunk0].

---

## Q37: How is PRRS associated with the breast cancer tumor immune microenvironment?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Gene-specific and prognostic models
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9277
- Top5 avg score: 0.5856
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How is PRRS associated with the breast cancer tumor immune microenvironment?

### GPT answer

If by **PRRS** you mean a **pyroptosis-related risk score/signature** in breast cancer, it is associated with the tumor immune microenvironment by reflecting how “immune-hot” or “immune-cold” a tumor is.

In general:

- **Low PRRS** tends to associate with a more active immune microenvironment:
  - higher immune-cell infiltration, especially cytotoxic T cells/NK cells;
  - stronger antigen presentation and inflammatory signaling;
  - higher expression of immune checkpoints such as PD-1/PD-L1/CTLA-4 in some studies;
  - potentially better responsiveness to immunotherapy.

- **High PRRS** is often linked to a more immunosuppressive or immune-poor microenvironment:
  - reduced cytotoxic immune infiltration;
  - enrichment of suppressive cells such as M2-like macrophages or Tregs;
  - weaker antitumor immune activity;
  - worse prognosis.

Mechanistically, pyroptosis-related genes can shape the breast cancer immune microenvironment through inflammasome activation, release of inflammatory cytokines such as IL-1β/IL-18, and DAMP-mediated immune-cell recruitment. Depending on context, this can either promote antitumor immunity or chronic tumor-promoting inflammation.

The exact direction can vary depending on how PRRS was defined in a given study.

### RAG answer

PRRS is associated with the breast cancer tumor immune microenvironment as an immune-enrichment versus immune-depletion axis: low PRRS tumors show greater stromal/immune content and broader immune-cell infiltration, whereas high PRRS tumors appear more “immune-cold,” with higher tumor purity and weaker antitumor immune features [PMC12685561:abstract:chunk0; PMC12685561:sec22:chunk0].
Mechanistically, PRRS is a paraptosis-related risk score built from six genes—USP10, NT5C, HSPB8, LCK, PI4KB, and GPR153—selected from paraptosis-related genes associated with overall survival in TCGA-BRCA [PMC12685561:sec18:chunk0; PMC12685561:sec19:chunk0]. When patients were stratified by this score, the high-risk group had lower estimated infiltration of CD8+ T cells, M1 macrophages, and Tregs, along with reduced activated B cells, CD4+ T cells, CD8+ T cells, and dendritic cells by ssGSEA [PMC12685561:sec22:chunk0]. In contrast, the low-risk group had higher immune and stromal scores, while the high-risk group had greater tumor purity [PMC12685561:sec22:chunk0].
Functionally, low PRRS was linked to higher expression of immune checkpoints and HLA family genes, as well as stronger immune-related signatures including cytolysis, T-cell co-stimulation/co-inhibition, antigen-presenting-cell co-inhibition, CCR, inflammatory promotion, parainflammation, and type II IFN-related responses [PMC12685561:sec22:chunk0]. This supports the interpretation that low-PRRS breast cancers have a more immune-active TME and may be more responsive to immunotherapy, whereas poor outcomes in high-PRRS patients may reflect reduced immune-cell presence and diminished immune defense capacity [PMC12685561:sec25:chunk1].
The evidence is mainly computational and correlative. The study argues that paraptosis-related biology may remodel the breast cancer TME, but it also notes that the precise signaling pathways, biomarkers, and cellular immune mechanisms linking paraptosis to immunotherapy response remain incompletely defined [PMC12685561:sec25:chunk0].

---

## Q38: How does mitocurcumin induce ROS/JNK-mediated paraptosis to overcome chemoresistance in NSCLC?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Recent therapeutic mechanisms
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9713
- Top5 avg score: 0.9134
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does mitocurcumin induce ROS/JNK-mediated paraptosis to overcome chemoresistance in NSCLC?

### GPT answer

Short answer: Mitocurcumin—a mitochondria-targeted curcumin derivative—kills chemoresistant NSCLC cells by accumulating in mitochondria, provoking mitochondrial ROS production that activates the JNK (c-Jun N‑terminal kinase) signaling cascade. Activated JNK drives ER/mitochondrial proteostasis collapse and cytoplasmic vacuolization characteristic of paraptosis (a caspase‑independent, protein‑synthesis–dependent cell death), thereby bypassing common apoptosis-based resistance mechanisms.

Mechanistic steps (concise):
- Mitochondrial targeting: a lipophilic cation moiety concentrates mitocurcumin in mitochondria, where it perturbs electron transport and increases superoxide/H2O2 generation.
- ROS increase: elevated mitochondrial ROS overwhelms antioxidant defenses, oxidizes proteins and lipids, and causes mitochondrial membrane potential disruption.
- JNK activation: ROS activates upstream MAP3Ks/MAP2Ks that phosphorylate JNK. Phosphorylated JNK transduces stress signals to downstream substrates.
- Paraptotic execution: JNK signaling promotes ER stress/protein misfolding and deregulates ER–mitochondria ion/protein homeostasis, producing extensive ER and mitochondrial swelling and large cytoplasmic vacuoles. This process is caspase‑independent and requires new protein synthesis (features of paraptosis).
- Evidence of dependence: blocking ROS (antioxidants) or inhibiting JNK prevents vacuolization and cell death, whereas caspase inhibitors do not, supporting a ROS→JNK→paraptosis axis.

How this overcomes chemoresistance:
- Bypasses apoptosis defects: many chemoresistant NSCLC cells evade apoptosis via Bcl‑2 family changes or caspase inhibition; paraptosis does not require caspase activation, so those blocks are ineffective.
- Avoids some drug‑efflux mechanisms: mitochondrial accumulation of a lipophilic cation can reduce effective drug export from the organelle and cell.
- Overcomes survival signaling: ROS/JNK–driven proteostasis collapse and organelle failure are lethal even when canonical survival pathways (e.g., PI3K/AKT, IAPs) are active.

Caveat: specific molecular intermediates (exact upstream MAP kinases, JNK substrates triggering vacuolization, and interactions with particular resistance proteins) may vary by cell line and have not been fully mapped in every NSCLC model.

### RAG answer

Mitochondrial-targeted curcumin (mitoC) initiates paraptotic death in NSCLC by first increasing intracellular reactive oxygen species (ROS), which drives activation (phosphorylation at Thr183/Tyr185) of the JNK kinase cascade [PMC13086902:sec12:chunk0; PMC13086902:abstract:chunk0].
Activated JNK then provokes organellar stress—robust ER stress/UPR signalling (BiP/HSPA5, CHOP/DDIT3 upregulation), loss of the paraptosis inhibitor Alix, increased protein ubiquitination, and pronounced ER and mitochondrial swelling/vacuolation—hallmarks of paraptosis [PMC13086902:sec11:chunk0; PMC13086902:sec14:chunk0]. JNK activation also promotes mitochondrial calcium overload via the mitochondrial calcium uniporter (MCU); mitoC-induced mitochondrial Ca2+ accumulation is reduced by JNK inhibition (SP600125), ROS scavenging (NAC), or pharmacological MCU blockade (MCUi4), linking ROS → JNK → MCU-mediated Ca2+ uptake to the paraptotic phenotype [PMC13086902:sec13:chunk0; PMC13086902:sec12:chunk0].
Because this death pathway is caspase-independent (pan‑caspase inhibitor Z‑VAD‑FMK did not rescue cell viability), mitoC can kill apoptosis-resistant cells, including cisplatin‑resistant A549R NSCLC cells, and inhibition of ROS or JNK reverses paraptosis markers and mitochondrial Ca2+ overload, confirming the requirement for the ROS–JNK axis [PMC13086902:sec12:chunk0; PMC13086902:sec14:chunk1; PMC13086902:sec15:chunk0].
Together these data indicate a mechanistic flow: mitoC → increased ROS → JNK phosphorylation → ER/mitochondrial proteostatic stress + MCU‑dependent mitochondrial Ca2+ overload → caspase‑independent paraptosis, providing a route to overcome chemoresistance in NSCLC. Mechanistic details (e.g., specific JNK isoforms, genetic validation of MCU) remain to be fully defined by follow-up knockdown/overexpression and in vivo studies [PMC13086902:sec14:chunk1; PMC13086902:sec15:chunk0].

---

## Q39: What is the relationship between ATP6V0D1, neuroblastoma chemoresistance, and ellipticine-induced cytoplasmic vacuolation?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Recent therapeutic mechanisms
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9924
- Top5 avg score: 0.9094
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What is the relationship between ATP6V0D1, neuroblastoma chemoresistance, and ellipticine-induced cytoplasmic vacuolation?

### GPT answer

- ATP6V0D1 encodes the d1 subunit of the V0 sector of the vacuolar H+-ATPase (V-ATPase), which is required for proton pumping that acidifies endosomes/lysosomes and drives vesicular trafficking.

- In neuroblastoma, high V-ATPase activity (including ATP6V0D1 function) promotes chemoresistance by maintaining acidic intracellular compartments that sequester and neutralize weak‑base chemotherapeutics, support autophagy-mediated survival, and enable pH‑dependent drug transport processes. Reducing ATP6V0D1 activity therefore tends to decrease drug sequestration and sensitize cells to chemotherapy.

- Ellipticine induces prominent cytoplasmic vacuolation in some cancer cells by disrupting endolysosomal/lysosomal homeostasis (causing swelling/accumulation of vacuoles and a non‑apoptotic, paraptosis‑like response). Because vacuole formation and lysosomal pH are governed by V-ATPase activity, the cellular response to ellipticine is modulated by ATP6V0D1 status.

- Mechanistic implication: modulating ATP6V0D1 alters both chemoresistance and ellipticine‑induced vacuolation. Loss or inhibition of ATP6V0D1 reduces lysosomal acidification and drug sequestration (sensitizing cells) and changes vacuolation dynamics; the precise effect on vacuole formation can be context‑dependent (V‑ATPase activity can be required for some vacuolation processes but its failure can also produce organelle swelling), so experiment-specific outcomes vary.

If you want, I can outline specific assays (lysosomal pH, intracellular drug localization, ATP6V0D1 knockdown/overexpression) to test these relationships in neuroblastoma cells.

### RAG answer

ATP6V0D1 is upregulated in ellipticine‑resistant neuroblastoma cells and drives chemoresistance by increasing V‑ATPase–dependent lysosomal acidification, which promotes lysosomal sequestration of ellipticine; concomitantly, ATP6V0D1 is required for the ellipticine‑induced massive cytoplasmic vacuolation (identified as ER swelling) via an acidification– and Ca2+‑dependent pathway [PMC12184147:sec13:chunk0; PMC12184147:abstract:chunk0; PMC12184147:sec17:chunk0].
Mechanistic flow: ellipticine is a weak base that preferentially accumulates in acidic lysosomes, a process enhanced by V‑ATPase activity (ATP6V0D1) leading to increased lysosomal capacity and drug sequestration in resistant cells [PMC12184147:sec17:chunk0; PMC12184147:sec14:chunk0]. Disruption of lysosomal acidification (by bafilomycin A1 or ATP6V0D1 knockdown) reduces lysosomal ellipticine uptake, redistributes ellipticine to the nucleus, and increases ellipticine cytotoxicity in resistant cells, indicating sequestration is a key resistance mechanism [PMC12184147:sec17:chunk0; PMC12184147:sec14:chunk0; PMC12184147:sec15:chunk0].
Connection to vacuolation and calcium: the ellipticine‑induced cytoplasmic vacuoles are ER swellings rather than paraptosis, and their formation requires intracellular Ca2+ (BAPTA blocks vacuolation). A plausible link is lysosomal Ca2+ release (e.g., via TRPML1), which depends on lysosomal acidification maintained by V‑ATPase; therefore ATP6V0D1 activity is necessary for this calcium‑dependent ER swelling and vacuole formation [PMC12184147:sec17:chunk0; PMC12184147:sec19:chunk2; PMC12184147:abstract:chunk0].
Functional consequences and specificity: silencing ATP6V0D1 (but not ATP6V1H) decreases lysosomal uptake and vacuolation, enhances apoptosis (cleaved caspase‑3), induces G2/M arrest, and suppresses proliferation/migration, thereby sensitizing resistant neuroblastoma cells to ellipticine—supporting ATP6V0D1 as a specific therapeutic target to overcome ellipticine resistance [PMC12184147:sec15:chunk0; PMC12184147:sec19:chunk1; PMC12184147:abstract:chunk0].

---

## Q40: Is ellipticine-induced cytoplasmic vacuolation related to paraptosis?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Recent therapeutic mechanisms
- Retrieval strength: HIGH
- Evidence diversity: HIGH
- Top1 score: 1.0000
- Top5 avg score: 0.4854
- Coverage: 0.8000
- Evidence count: 8
- Normalized retrieval query: Is ellipticine-induced cytoplasmic vacuolation related to paraptosis?

### GPT answer

Short answer: Possibly — ellipticine-induced cytoplasmic vacuolation could reflect paraptosis, but you cannot assume that without testing. I don’t have a specific study to cite here, so the relationship is conditional on whether the vacuolation meets paraptosis criteria.

Mechanistic checklist to distinguish paraptosis from other vacuole-producing processes:
- Caspase independence: paraptosis occurs without caspase activation and is not blocked by pan‑caspase inhibitors (zVAD‑fmk).
- Organelle origin of vacuoles: paraptotic vacuoles arise from swelling/dilation of the endoplasmic reticulum and/or mitochondria (EM or co‑localization with ER/mitochondrial markers), not from double‑membrane autophagosomes.
- Protein synthesis dependence: paraptosis typically requires new protein synthesis and is inhibited by cycloheximide.
- MAPK dependence: many paraptosis models require MAPK/ERK or JNK signaling and are sensitive to MAPK pathway inhibitors.
- Absence of apoptotic/autophagic markers: no chromatin condensation/ DNA laddering (apoptosis) and no canonical autophagy marker activation (e.g., LC3‑II lipidation with autophagic flux).
- Inhibition/augmentation by known modulators: overexpression of Alix/ AIP1 blocks paraptosis in established systems.

Practical tests to run on ellipticine-treated cells:
- Measure caspase activity and effect of zVAD on vacuolation and cell death.
- EM and immunofluorescence for ER (calreticulin, BiP) and mitochondrial markers to show vacuole origin.
- Test cycloheximide and MAPK inhibitors for suppression of vacuolation.
- Check LC3 processing, p62 levels and autophagic flux to rule out autophagy.
- Assess ROS/ER stress markers (BiP, CHOP, eIF2α phosphorylation) because ellipticine can cause ROS/ER stress that also produce vacuolation.

Conclusion: If ellipticine‑treated cells display caspase‑independent, cycloheximide‑sensitive ER/mitochondrial swelling, MAPK dependence, and lack apoptotic/autophagic markers, the vacuolation is consistent with paraptosis. Otherwise the vacuoles may reflect ER stress, necrosis, or non‑canonical autophagy. I’m uncertain whether ellipticine routinely induces paraptosis without the above validating data.

### RAG answer

No — ellipticine-induced cytoplasmic vacuolation in the neuroblastoma models described does not fully comport with classical paraptosis, although it shares some upstream features (notably ER dilation and Ca2+ dependence) that make it “paraptosis‑like.”
Mechanistic synthesis: ellipticine is sequestered into lysosomes in a V‑ATPase–dependent manner and rapidly induces large cytoplasmic vacuoles that co‑localize with ER markers (not mitochondria) and are suppressed by ATP6V0D1 knockdown or by disrupting lysosomal acidification, indicating a lysosome → ER axis [PMC12184147:sec17:chunk0; PMC12184147:sec19:chunk2]. Chelation of intracellular Ca2+ with BAPTA blocks ellipticine‑induced vacuolation, implicating Ca2+ flux in vacuole formation and suggesting a role for lysosomal Ca2+ release channels such as TRPML1 (not proven, but proposed) downstream of V‑ATPase activity [PMC12184147:sec18:chunk0; PMC12184147:sec19:chunk2].
Why this differs from canonical paraptosis: classical paraptosis is typically driven by proteostasis/UPR perturbation (BiP/GRP78 upregulation, increased misfolded/polyubiquitinated proteins), is often inhibited by the translation inhibitor cycloheximide, and may involve Alix downregulation and MAPK signaling [PMC7873879:sec0:chunk0; PMC11546839:sec10:chunk0; PMC11533606:sec1:chunk0]. In contrast, ellipticine treatment did not increase BiP, p‑PERK, Alix changes, or polyubiquitinated proteins, and cycloheximide failed to prevent vacuolation — arguing against UPR/proteotoxicity‑driven paraptosis as the primary mechanism here [PMC12184147:sec18:chunk0].
Implication: ellipticine causes ER‑dilatory, Ca2+‑dependent vacuolation that is mechanistically linked to lysosomal drug sequestration and V‑ATPase function, but lacks key biochemical hallmarks of paraptosis; therefore it is best described as a paraptosis‑like, yet distinct, vacuolization process in these cells [PMC12184147:sec17:chunk0; PMC12184147:sec18:chunk0; PMC12184147:sec19:chunk2; PMC11546839:sec9:chunk0].

---

## Q41: Can alpha-Hederin suppress chemo-resistant colorectal cancer cells through Ca2+/MAPK-mediated paraptosis?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Recent therapeutic mechanisms
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9782
- Top5 avg score: 0.8404
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: Can alpha-Hederin suppress chemo-resistant colorectal cancer cells through Ca2+/MAPK-mediated paraptosis?

### GPT answer

Short answer: Possibly — it is mechanistically plausible that α‑hederin can suppress chemo‑resistant colorectal cancer (CRC) cells by inducing Ca2+/MAPK‑mediated paraptosis, but definitive proof in chemo‑resistant CRC requires more targeted experiments and in vivo validation.

Mechanistic rationale (concise):
- Paraptosis is a caspase‑independent programmed cell death characterized by extensive cytoplasmic vacuolization from ER/mitochondrial swelling, requires new protein synthesis, and is frequently linked to disturbances in intracellular Ca2+ and activation of MAPK pathways (ERK/JNK/p38).  
- α‑Hederin, a triterpenoid saponin, has been reported to cause ER stress, raise intracellular Ca2+ and activate MAPK signaling in cancer cells in vitro, mechanisms that could trigger paraptosis rather than classical apoptosis.  
- Because paraptosis bypasses caspase‑dependent apoptosis, it is a plausible way to kill chemo‑resistant CRC cells that have apoptotic pathway defects.

What would constitute definitive evidence:
- In chemo‑resistant CRC cell lines: α‑hederin treatment causes (i) rapid intracellular Ca2+ elevation, (ii) MAPK (ERK/JNK/p38) phosphorylation, (iii) extensive cytoplasmic vacuolization with ER/mitochondrial swelling on EM, (iv) lack of caspase activation and DNA laddering, and (v) dependence on protein synthesis (blocked by cycloheximide).  
- Functional reversal: protection by Ca2+ chelation (e.g., BAPTA‑AM) and by specific MAPK inhibitors (or genetic knockdown), but not by pan‑caspase inhibitors (z‑VAD‑fmk).  
- In vivo tumor models of chemo‑resistant CRC showing tumor regression with acceptable toxicity.

Practical note: The idea is promising as a way to circumvent apoptosis resistance, but translation will require rigorous mechanistic confirmation and safety studies. If you want, I can outline a specific experimental plan (cell lines, assays, controls) to test this hypothesis.

### RAG answer

Yes — the retrieved data support that α‑hederin (α‑hed) suppresses chemo‑resistant colorectal cancer (CRC) by inducing a Ca2+‑ and MAPK‑dependent paraptotic program.
Mechanism (trigger → pathway → phenotype): α‑hed binds GPCRs and activates a PLCβ3/IP3R‑dependent cascade that mobilizes ER Ca2+, leading to intracellular Ca2+ surge and downstream MAPK activation; this pathway produces characteristic paraptotic changes (extensive cytoplasmic vacuolation, ER and mitochondrial dilation) and downregulation of the paraptosis inhibitor Alix [PMC11043672:abstract:chunk0; PMC11043672:sec19:chunk0; PMC11043672:sec13:chunk0]. Pharmacologic blockade of Ca2+ handling (Na+/Ca2+ exchange inhibitor SEA0400) prevented vacuolation and reduced α‑hed cytotoxicity, supporting a causal role for Ca2+ signaling in the cell death process [PMC11043672:sec19:chunk0].
Efficacy against chemo‑resistant CRC: α‑hed reduced viability and induced paraptosis‑like vacuolation equivalently in 5‑FU–resistant HT‑29 clones and parental cells, with dose‑dependent suppression of Alix in resistant cells, indicating activity against apoptosis‑resistant clones in vitro [PMC11043672:sec17:chunk0; PMC11043672:sec13:chunk0]. In vivo, α‑hed (1.5 mg/kg) significantly decreased tumor volume and weight in 5‑FU‑resistant HT‑29 xenografts—showing greater suppression than 5‑FU—with histologic evidence of vacuolation and reduced Ki67/Alix consistent with paraptosis‑mediated tumor control [PMC11043672:sec18:chunk0].
Implication: Taken together, these data indicate α‑hederin can overcome 5‑FU resistance in CRC via GPCR‑mediated Ca2+ release and MAPK activation that trigger paraptosis, supporting its consideration as an alternative therapeutic strategy for apoptosis‑resistant CRC [PMC11043672:sec20:chunk0; PMC11043672:abstract:chunk0].

---

## Q42: How does diphenyl disulfide induce ROS-mediated ER-stress paraptosis in breast cancer cells?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Recent therapeutic mechanisms
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9773
- Top5 avg score: 0.9561
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does diphenyl disulfide induce ROS-mediated ER-stress paraptosis in breast cancer cells?

### GPT answer

Briefly, diphenyl disulfide (PhSSPh) drives a redox cascade that converts ER proteostasis failure into caspase‑independent, vacuole‑forming cell death (paraptosis). Mechanistically:

1. Thiol–disulfide chemistry and ROS generation
   - PhSSPh undergoes thiol–disulfide exchange with cellular thiols (glutathione and protein cysteines) and/or redox cycling, depleting GSH and increasing reactive oxygen species (superoxide/H2O2).
2. Oxidative disruption of ER folding
   - Elevated ROS oxidize ER protein thiols and chaperones, impairing oxidative protein folding and causing accumulation of misfolded proteins in the ER lumen.
3. Unfolded protein response and sustained ER stress
   - The misfolded‑protein load activates the UPR sensors (PERK/IRE1/ATF6). If stress is prolonged/intense, adaptive responses fail and ER architecture becomes disrupted.
4. ER calcium dysregulation and organelle swelling
   - ROS and ER stress promote ER Ca2+ release (via redox modulation of SERCA/IP3R/RYR), raising cytosolic and mitochondrial Ca2+, causing mitochondrial dysfunction and osmotic/structural swelling of ER and mitochondria that produce large cytoplasmic vacuoles.
5. Paraptotic execution (caspase‑independent)
   - The outcome is caspase‑independent cytoplasmic vacuolation (paraptosis): extensive ER/mitochondrial dilation, loss of clonogenicity, but little DNA laddering or caspase activation. Paraptosis typically requires new protein synthesis and involves MAPK signaling (ERK/JNK) downstream of ROS/ER stress.
6. Experimental validation (typical)
   - Antioxidants (e.g., NAC) or agents that restore thiol redox block ROS, ER stress markers and vacuolation; caspase inhibitors do not prevent death; inhibitors of translation or MAPKs attenuate vacuole formation.

Caveat: the broad steps above reflect the commonly observed ROS → ER stress → Ca2+ dysregulation → organelle swelling pathway that drives paraptosis; the precise dominant UPR sensor(s) and signaling intermediates engaged by PhSSPh can vary by breast cancer cell line and experimental conditions. I’m uncertain about any unique, compound‑specific binding partners beyond general thiol reactivity.

### RAG answer

DPDS induces paraptosis in breast cancer cells by first raising intracellular ROS, which then provokes ER stress and consequent paraptotic morphology and death.
Mechanistic flow — trigger → pathway → phenotype:
- Trigger (ROS): DPDS treatment increases intracellular superoxide/ROS in MDA‑MB‑231 and MCF‑7 cells (DHE staining), and ROS scavenging with NAC substantially rescues cell viability, indicating ROS are required for DPDS cytotoxicity [PMC13181374:sec13:chunk0][PMC13181374:sec15:chunk2].
- Pathway (ROS → ER stress): The ROS generated by DPDS upregulate canonical ER stress markers (BIP/GRP78, IRE‑1α, CHOP and increased calnexin), and NAC cotreatment attenuates DPDS‑induced BIP expression, showing that ER stress induction is downstream of ROS [PMC13181374:sec15:chunk1][PMC13181374:sec14:chunk0].
- Phenotype (ER stress → paraptosis): ER stress is associated with paraptotic features after DPDS exposure — prominent cytoplasmic vacuolization, ER/mitochondrial swelling, and downregulation of the paraptosis marker Alix. NAC reduces vacuolization and restores Alix, and pharmacologic ER‑stress inhibitors (HA15, MAC3946) partially rescue viability and colony formation, supporting that ROS→ER stress drives paraptotic cell death rather than classical apoptosis [PMC13181374:abstract:chunk0][PMC13181374:sec14:chunk0][PMC13181374:sec12:chunk0].
Implication: Together these data indicate DPDS kills breast cancer cells via a ROS‑dependent activation of ER stress that initiates paraptosis (nonapoptotic vacuolization and organelle swelling), a pathway that may help overcome apoptosis resistance in breast cancer [PMC13181374:sec16:chunk0][PMC13181374:sec15:chunk2]. Evidence is derived from ROS measurements, marker changes, morphological readouts, NAC reversal, and partial protection by ER stress inhibitors.

---

## Q43: How does a cyclometalated iridium(III) complex induce paraptosis in triple-negative breast cancer cells?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Recent therapeutic mechanisms
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9579
- Top5 avg score: 0.7755
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does a cyclometalated iridium(III) complex induce paraptosis in triple-negative breast cancer cells?

### GPT answer

Short answer: the complex enters TNBC cells, accumulates on/near endoplasmic reticulum and mitochondria, and triggers oxidative and proteostatic stress that collapses ER/mitochondrial homeostasis (Ca2+ dysregulation, loss of mitochondrial membrane potential, ER swelling). That cascade—driven by ROS generation and often by inhibition of proteasome/thiol redox enzymes—activates MAPK signaling and an unfolded‑protein/ER stress response, produces massive cytoplasmic vacuolization (from swollen ER/mitochondria), and kills cells in a caspase‑independent, protein‑synthesis‑dependent manner characteristic of paraptosis.

Mechanistic steps (concise)
- Uptake and subcellular targeting: many cyclometalated Ir(III) complexes localize to ER and/or mitochondria.  
- Oxidative/redox perturbation: the complex produces ROS (or inhibits redox enzymes), depleting antioxidant capacity and damaging organelle membranes.  
- Mitochondrial dysfunction and Ca2+ release: ROS and membrane damage lower mitochondrial membrane potential and release Ca2+, stressing the ER and mitochondria.  
- Proteostasis collapse and ER stress: accumulation of damaged/misfolded proteins (sometimes aided by proteasome inhibition) activates the unfolded protein response and causes ER dilatation.  
- MAPK signaling and paraptotic execution: stress‑activated kinases (e.g., ERK/JNK family) propagate a caspase‑independent death program that requires new protein synthesis and results in large ER/mitochondrial vacuoles and cell lysis rather than apoptotic features.

Caveat: the precise dominant trigger (light‑activated ROS vs dark redox enzyme inhibition, primary organelle target, and specific kinase targets) depends on the particular Ir(III) ligand set and experimental conditions. If you want, I can summarize evidence for a specific cyclometalated Ir(III) compound.

### RAG answer

CIr2, a cyclometalated iridium(III) complex, induces paraptosis in triple‑negative breast cancer (TNBC) cells by first accumulating in mitochondria and provoking mitochondrial dysfunction (loss of membrane potential, excessive ROS generation, and ATP depletion). These mitochondrial perturbations trigger ER stress and activate p38 MAPK signaling, producing mitochondrial–ER crosstalk that culminates in extensive cytoplasmic vacuolation, mitochondrial swelling and ER dilation and, ultimately, caspase‑independent paraptotic cell death [PMC12883731:sec36:chunk0; PMC12883731:sec35:chunk0; PMC12883731:sec32:chunk0].
Mechanistically: CIr2 mitochondrial localization was demonstrated experimentally, and the resulting bioenergetic collapse and oxidative stress act as the proximal trigger → ER stress (including transcriptional signatures) and p38 MAPK activation are the downstream signaling events → the cellular phenotype is classic paraptosis (vacuolation, swollen mitochondria/ER) rather than apoptosis (caspase independent) [PMC12883731:sec7:chunk0; PMC12883731:abstract:chunk0; PMC12883731:sec35:chunk0; PMC12883731:sec32:chunk0].
Therapeutic implication: CIr2 selectively kills TNBC cells in vitro and suppresses TNBC xenograft growth in vivo with minimal systemic toxicity, supporting its potential as a paraptosis‑inducing agent to overcome apoptosis resistance; identification of the precise molecular targets of CIr2 remains to be addressed in future studies [PMC12883731:sec36:chunk0; PMC12883731:abstract:chunk0].

---

## Q44: Why can hemicyanine electrophiles induce paraptosis?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Recent therapeutic mechanisms
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 1.0000
- Top5 avg score: 0.8371
- Coverage: 0.7500
- Evidence count: 8
- Normalized retrieval query: Why can hemicyanine electrophiles induce paraptosis?

### GPT answer

Paraptosis is a non‑apoptotic programmed‑cell‑death mode characterized by extensive cytoplasmic vacuolization caused by swelling of endoplasmic reticulum (ER) and/or mitochondria, absence of caspase activation, and dependence on MAPK signaling and new protein synthesis. Hemicyanine electrophiles can induce paraptosis by a combination of physicochemical and covalent‑chemistry effects:

- Organellar accumulation: hemicyanine scaffolds are lipophilic cations that preferentially accumulate in mitochondria and associate with ER membranes, delivering the electrophilic warhead to these organelles.
- Covalent modification of thiols/proteins: the electrophile reacts with nucleophilic residues (especially cysteines) on ER/mitochondrial proteins, impairing chaperones, ion pumps (e.g., SERCA), and components of proteostasis pathways.
- Proteostasis collapse and ER stress: protein modification and/or inhibition of ER‑associated degradation leads to accumulation of misfolded proteins, triggering ER stress and unfolded‑protein responses that favor organelle swelling rather than apoptotic signaling.
- Ca2+ dysregulation and mitochondrial dysfunction: ER perturbation releases Ca2+ into the cytosol and mitochondria, causing mitochondrial swelling, bioenergetic failure and reactive oxygen species (ROS) production; ROS further damages proteins and lipids.
- MAPK activation and translational dependence: stress signaling (MAPKs) and continued protein synthesis are engaged, which are required for the vacuolization cascade of paraptosis.
- Lack of caspase activation: because the primary insult is organelle and proteostasis disruption rather than classical apoptotic signaling, caspases are not activated and apoptotic features are absent.

In short, hemicyanine electrophiles induce paraptosis by targeting ER/mitochondrial proteins through covalent modification and organelle‑targeted disruption (proteostasis collapse, Ca2+/redox imbalance) that produces organelle swelling and vacuolization rather than caspase‑dependent apoptosis. Exact molecular targets and the relative contribution of ROS, specific protein adducts, and ion‑pump inhibition vary with the compound and remain under investigation.

### RAG answer

Hemicyanine electrophiles induce paraptosis because their tuned electrophilicity allows them to act as covalent Michael acceptors that modify protein cysteine thiols, perturbing thiol proteostasis and vesicle/ER homeostasis and thereby triggering the paraptotic cascade (ER vacuolation → mitochondrial dysfunction → caspase‑independent death). Key mechanistic elements are: electrophile → cysteine modification → disruption of trafficking/ER function and increased mitochondrial superoxide → paraptotic morphology and cell death [PMC12426919:sec1:chunk0; PMC12426919:sec6:chunk0; PMC12426919:sec4:chunk0; PMC12426919:abstract:chunk0].
Support for this chain: cytotoxicity and vacuolation across hemicyanine analogs scale with their electrophilicity, consistent with covalent reactivity toward nucleophilic cysteines (they are Michael acceptors) [PMC12426919:sec1:chunk0]. Gel-based and competitive ABPP shows compound 2 blocks cysteine labeling of soluble proteins in a dose-dependent manner, indicating direct engagement of ligandable cysteines in the proteome [PMC12426919:sec6:chunk0]. Functionally, compound 2 treatment increases mitochondrial superoxide and produces canonical paraptosis features (extensive ER dilation/vacuolation, mitochondrial swelling, caspase‑independent death) [PMC12426919:sec4:chunk0; PMC12426919:sec0:chunk1; PMC12426919:abstract:chunk0].
Proteomic ABPP identified candidate targets linked to vesicle trafficking and ER morphology—most notably SEC23A and GDI1—which plausibly connect cysteine modification to disrupted ER-to-Golgi trafficking and ER vacuolation that characterize paraptosis; the lead compound also shows some selectivity (limited engagement of abundant nucleophilic PDIs) suggesting a degree of target specificity underlying the phenotype [PMC12426919:sec7:chunk0; PMC12426919:sec8:chunk0; PMC12426919:abstract:chunk0]. Note that current compounds require relatively high concentration/long exposure to induce paraptosis, so potency and selectivity remain areas for optimization [PMC12426919:sec8:chunk0].

---

## Q45: How does a ROS-amplifying nanocatalyst induce multi-organelle stress paraptosis and enhance cancer immunotherapy?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Recent therapeutic mechanisms
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9376
- Top5 avg score: 0.8559
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does a ROS-amplifying nanocatalyst induce multi-organelle stress paraptosis and enhance cancer immunotherapy?

### GPT answer

Briefly: the nanocatalyst amplifies reactive oxygen species (ROS) inside tumor cells, producing an oxidative “burst” that simultaneously damages multiple organelles, drives a caspase‑independent paraptotic program (massive cytoplasmic vacuolization from ER/mitochondrial swelling) and converts dying cancer cells into an immunogenic source of antigens and danger signals that boost anti‑tumor immunity.

Mechanism (stepwise, mechanistic):
- ROS amplification: the particle catalyzes tumor‑abundant substrates (e.g., H2O2) via Fenton/Fenton‑like chemistry and/or photochemical activation, and often depletes intracellular antioxidants (GSH). The result is sustained, high local levels of •OH/other ROS.
- Multi‑organelle oxidative damage: excessive ROS oxidize proteins, lipids and membranes across organelles.
  - Endoplasmic reticulum (ER): oxidative protein misfolding and disrupted Ca2+ homeostasis cause ER swelling and an unfolded‑protein response that fails, producing ER vacuolization.
  - Mitochondria: ROS cause loss of membrane potential, electron transport dysfunction and mitochondrial swelling; mitochondrial proteotoxic stress compounds cellular stress.
  - Lysosomes/other membranes: ROS and lipid peroxidation promote membrane permeabilization and trafficking defects, contributing to cytoplasmic vacuole formation.
- Paraptosis induction: these combined stresses produce the hallmark morphological and biochemical features of paraptosis — extensive ER/mitochondrial‑derived vacuolization and cell death that is caspase‑independent, often associated with MAPK pathway activation and proteostasis collapse rather than classical apoptotic cascades.
- Immunogenic conversion: ROS‑driven paraptotic death is accompanied by release/exposure of damage‑associated molecular patterns (DAMPs) and tumor antigens (for example, extracellular ATP, HMGB1 release and surface exposure of endoplasmic reticulum chaperones such as calreticulin). These signals promote dendritic cell maturation, antigen uptake and cross‑presentation.
- Enhanced immunotherapy: the increased antigen availability and DAMP‑mediated DC activation recruit and prime cytotoxic T cells and shift the tumor microenvironment toward immune stimulation. That synergizes with systemic immunotherapies (e.g., checkpoint blockade) by increasing tumor antigenicity and T cell infiltration, improving treatment responses.

If you want, I can sketch a diagram of the sequence or summarize how altering nanoparticle composition (iron vs. copper catalysts, GSH‑consuming coatings, photoactivation) changes these effects.

### RAG answer

TF‑Fe@LC (porous Fe3O4 nanoclusters coated with a pH‑labile Fe3+–tannic acid network and loaded with lactate oxidase (LOD) and the mitochondrial uncoupler CCCP) triggers a self‑reinforcing oxidative burst in tumors by acid‑triggered release of Fe2+/Fe3+, LOD and CCCP. LOD converts intratumoral lactate into H2O2, which supplies substrate for Fe‑mediated Fenton/Fenton‑like reactions to produce ·OH; concurrently CCCP collapses mitochondrial membrane potential and promotes mitochondrial ROS leakage, synergizing with CDT to amplify intracellular ROS (oxidative outburst) [PMC13159107:abstract:chunk0; PMC13159107:sec0:chunk1; PMC13159107:sec8:chunk0].
The amplified ROS causes multi‑organelle dysfunction: severe mitochondrial damage (Δψ loss, ATP depletion) and propagation of oxidative stress to the ER, activating the PERK → p‑eIF2α → ATF4 (→ CHOP) ER‑stress axis, while ROS and mitochondrial injury block autophagic flux by inhibiting autophagosome–lysosome fusion (elevated LC3‑II/I with sustained p62, ATG5, Beclin1). These concurrent perturbations produce extensive cytoplasmic vacuolization and caspase‑independent paraptotic cell death driven by a ROS‑driven feed‑forward loop (mitochondria‑associated ER stress → blocked mitophagy/autophagy → more ROS) [PMC13159107:sec3:chunk1; PMC13159107:sec4:chunk0; PMC13159107:sec4:chunk1; PMC13159107:sec8:chunk0].
Paraptosis induced by TF‑Fe@LC is immunogenic: it elicits DAMP release/exposure (HMGB1 release and calreticulin exposure) that matures dendritic cells (increased CD11c+CD80+ and CD11c+CD86+), enhances T‑cell priming, and thus converts local oxidative tumor damage into systemic antitumor immunity. In vivo, TF‑Fe@LC combined with αPD‑L1 produced markedly improved control of both primary and distant tumors (reported inhibition rates up to ~90.2% primary and ~84.5% distant), supporting the concept that ROS‑amplified, multi‑organelle stress‑driven paraptosis can potentiate cancer immunotherapy [PMC13159107:sec4:chunk1; PMC13159107:sec6:chunk1; PMC13159107:abstract:chunk0].

---

## Q46: What is the crosstalk between autophagy and paraptosis in cancer therapy?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Emerging applications and cancer subtypes
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9486
- Top5 avg score: 0.9299
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: What is the crosstalk between autophagy and paraptosis in cancer therapy?

### GPT answer

Short answer
Autophagy and paraptosis are interconnected stress-response programs that can cooperate or antagonize each other in cancer cells. Both are triggered by overlapping upstream insults (ER stress, proteotoxic stress, ROS, altered Ca2+, MAPK activation) and share signaling nodes, so modulation of one pathway often changes the other and can shift a tumor cell between survival and non‑apoptotic death.

Mechanistic overview (concise)
- Definitions
  - Autophagy: an evolutionarily conserved lysosomal degradation pathway (ULK1 → ATG proteins → LC3 lipidation → autophagosome → lysosome) that usually promotes stress adaptation and can be cytoprotective or, in some cases, contribute to cell death.
  - Paraptosis: a caspase‑independent, non‑apoptotic death characterized by extensive cytoplasmic vacuolation from ER/mitochondrial swelling, requires new protein synthesis and often involves MAPK (ERK/JNK) signaling; it is not executed by classical apoptotic caspases.

- Shared upstream triggers and signaling
  - ER stress / UPR (PERK‑eIF2α‑ATF4, IRE1‑JNK) and proteasome inhibition lead to accumulation of misfolded proteins, which induce both autophagy (to clear aggregates) and paraptotic vacuolation (ER/mitochondrial swelling).
  - ROS and altered Ca2+ promote mitochondrial dysfunction and activate both autophagy and paraptotic pathways.
  - MAPK pathways (ERK, JNK) can drive paraptosis and also regulate autophagy (e.g., JNK phosphorylates Bcl‑2, releasing Beclin‑1).

Modes of crosstalk
- Protective autophagy limiting paraptosis: autophagy clears misfolded proteins, damaged organelles and excessive ER stress, thereby reducing the stimulus for vacuolation and delaying or preventing paraptotic death.
- Autophagy facilitating paraptosis or non‑apoptotic death: in some contexts autophagic flux contributes to vacuole biogenesis or degrades anti‑death factors, allowing paraptosis to proceed; transient autophagy induction can precede and be permissive for paraptosis.
- Signal integration at nodes: shared regulators (e.g., mTORC1, Beclin‑1/Bcl‑2, JNK, Ca2+-dependent effectors) determine whether the cellular outcome is adaptive autophagy or paraptotic death. Protein synthesis requirement for paraptosis (sensitivity to cycloheximide) contrasts with autophagy’s degradative program.

Therapeutic implications
- Rational combinations: inducing paraptosis in apoptosis‑resistant tumors can be advantageous, but concurrent protective autophagy may blunt efficacy. Combining paraptosis inducers with autophagy inhibitors (e.g., chloroquine/HCQ or genetic inhibition of ATG proteins) can increase cancer cell killing in some models.
- Context dependence: in other settings stimulating autophagy may help kill tumor cells or sensitize them to paraptosis inducers. The best approach depends on tumor type, the specific inducer, and whether autophagy is primarily cytoprotective or pro‑death in that context.
- Biomarkers and readouts to guide therapy: monitor LC3‑II, p62/SQSTM1 and autophagic flux for autophagy; look for extensive ER/mitochondrial vacuolation, lack of caspase activation, and cycloheximide sensitivity for paraptosis.

Limitations and uncertainties
- The balance between protective versus permissive roles of autophagy in paraptosis is highly context‑dependent and incompletely mapped; mechanistic specificities differ by cell line, stimulus and tumor microenvironment.
- More mechanistic and in vivo data are needed to define when to inhibit or stimulate autophagy to maximize paraptosis‑based cancer therapy.

If you want, I can summarize actionable experimental strategies (drug combos, assays, expected outcomes) for a specific tumor model you’re working with.

### RAG answer

Autophagy and paraptosis are functionally linked in cancer cells: both can be triggered by ER/mitochondrial stress (e.g., unresolved proteotoxicity, ROS, calcium/ion imbalance), but autophagy typically acts as a cytoprotective, homeostatic response while paraptosis is a caspase‑independent death program marked by ER/mitochondrial swelling and massive cytoplasmic vacuolation driven in part by MAPK signalling [PMC12985128:abstract:chunk0; PMC12985128:sec16:chunk0; PMC12985128:sec0:chunk0].
Mechanistically, the unfolded protein response (UPR) sits upstream of both pathways: PERK‑dependent UPR signalling can promote survival autophagy, whereas loss of PERK or persistent unresolved ER stress can shift cells toward paraptosis (for example via sec61β), and UPR effectors such as CHOP/DDIT4 can amplify proteotoxic stress that favours paraptosis [PMC12985128:abstract:chunk0; PMC12985128:sec3:chunk0]. Conversely, suppression of autophagic flux can allow accumulation of misfolded proteins/organellar damage and thereby precipitate paraptotic features; paraptosis itself has been reported to inhibit late stages of autophagy in some settings, indicating bidirectional regulation [PMC12985128:sec17:chunk0; PMC12985128:sec16:chunk0].
Experimental data support a context‑dependent relationship: genetic knockdown of core autophagy genes (e.g., beclin‑1, ATG5) or pharmacologic blockade of survival autophagy (e.g., NIM811, elaiophylin) increases susceptibility to paraptosis in several cancer models, suggesting that autophagy inhibition can sensitize cells to paraptotic death via enhanced ER/mitochondrial stress and MAPK activation; however, some paraptosis-inducing agents are unaffected or even attenuated by autophagy inhibitors, so the interaction depends on cell type and the inducing stimulus [PMC12985128:sec17:chunk0; PMC12985128:sec16:chunk0].
Therapeutic implication: targeting the switch—either by combining paraptosis inducers with autophagy inhibitors or by selectively blocking survival autophagy in ER/mitochondrial‑stressed tumours—is a promising strategy to overcome apoptosis resistance, but translation is limited by lack of universal paraptosis markers, cell‑specific responses, and incomplete omics‑level understanding; preclinical ATG‑knockout models and focused studies on organelle‑specific autophagy (e.g., mitophagy) are recommended to refine this approach [PMC12985128:sec20:chunk0; PMC12985128:sec19:chunk1; PMC12985128:sec19:chunk0]. Evidence is promising but context‑dependent and further mechanistic and translational work is needed.

---

## Q47: Can paraptosis be used as a senolytic mechanism?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Emerging applications and cancer subtypes
- Retrieval strength: MEDIUM
- Evidence diversity: HIGH
- Top1 score: 0.6400
- Top5 avg score: 0.4435
- Coverage: 0.3333
- Evidence count: 8
- Normalized retrieval query: Can paraptosis be used as a senolytic mechanism?

### GPT answer

Short answer: Possibly — mechanistically plausible but not yet a validated senolytic strategy. Evidence is limited and selective application would be required.

Why it’s plausible
- Paraptosis is a programmed, non‑apoptotic cell‑death modality characterized by extensive cytoplasmic vacuolization, ER and mitochondrial swelling, MAPK/ERK signaling, requirement for de novo protein synthesis, and independence from caspase activation.  
- Many senescent cells are apoptosis‑resistant (upregulated BCL‑2 family and other anti‑apoptotic mechanisms) but are under chronic proteotoxic/ER and mitochondrial stress and have altered secretory/ER demands (the SASP). Those features could make senescent cells more susceptible than normal cells to triggers that cause ER/mitochondrial collapse and paraptosis.  
- Because paraptosis does not rely on caspases, it could in principle bypass the canonical apoptotic resistance that limits some current senolytics.

Key mechanistic opportunities
- Induce unresolved ER stress or proteostasis collapse in senescent cells (e.g., exacerbate protein synthesis/aggregation or inhibit proteasome/ERAD), which can drive the vacuolization/organellar swelling seen in paraptosis.  
- Activate MAPK/ERK signaling or perturb calcium handling and mitochondrial function to tip stressed senescent cells into paraptotic death.  
- Exploit senescent‑cell reliance on heightened secretory/protein‑folding capacity (SASP) as a selective vulnerability.

Major caveats and challenges
- Selectivity: normal proliferating or secretory cells could also undergo paraptosis if exposed to the same triggers; achieving senescent‑cell specificity is the central hurdle.  
- Inflammation/immunogenicity: the downstream immune consequences of paraptotic death (vs apoptosis) are not fully characterized and could be harmful or beneficial depending on context.  
- Limited empirical validation: paraptosis as a therapeutic strategy has been mainly explored in cancer models; direct, rigorous tests in senescent cells and in vivo senolytic settings are sparse.  
- Safety: systemic induction of ER/mitochondrial collapse risks organ toxicity.

What would be needed to test it
- In vitro screens comparing induction of paraptosis markers (vacuolization, ER/mitochondrial swelling, caspase independence, sensitivity to protein synthesis inhibitors) in matched senescent versus non‑senescent cells.  
- Mechanistic probes to confirm dependence on pathways (MAPK/ERK, proteostasis, calcium) and to identify senescence‑specific mediators.  
- In vivo models assessing efficacy, tissue selectivity, and inflammatory/toxic sequelae.

Conclusion
Paraptosis offers a rational alternative route to kill apoptosis‑resistant senescent cells, but it remains a theoretical/early‑stage approach. It could work if one can find agents or delivery methods that selectively push senescent cells into paraptotic collapse without unacceptable off‑target damage; rigorous experimental validation is required. I’m not aware of conclusive demonstrations of paraptosis‑based senolytics in vivo.

### RAG answer

No — based on the retrieved literature, evidence is insufficient to conclude that paraptosis can be used as a senolytic mechanism.
Paraptosis is a caspase‑independent form of programmed cell death characterized by ER and/or mitochondrial swelling and extensive cytoplasmic vacuolization, driven in many contexts by MAPK signaling and by perturbations of proteostasis, redox balance, mitochondrial Ca2+ and ROS generation [PMC10789732:abstract:chunk0; paper_8b08118292ccc1f6:abstract:chunk0]. It can be induced by diverse small molecules, natural products and nanomedicines and has been proposed as a way to kill apoptosis‑resistant cancer cells [paper_25e3ec5913603f7c:abstract:chunk0; PMC11533606:abstract:chunk0; PMC10308048:abstract:chunk0].
However, none of the retrieved nodes report experiments on senescent cells or demonstrate selective elimination of senescent (therapy‑resistant but non‑proliferative) cells. While the mechanistic features of paraptosis (proteostasis/ER–mitochondrial stress, ROS) make it theoretically plausible to target cells with altered proteostasis, the literature here only discusses cancer targeting and resistance circumvention, not senolysis or senescence specificity [paper_8b08118292ccc1f6:abstract:chunk0; PMC11533606:sec22:chunk0]. Therefore, evidence insufficient.

---

## Q48: How does Rhodiola rosea extract exert senolytic activity through paraptosis?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Emerging applications and cancer subtypes
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9921
- Top5 avg score: 0.7845
- Coverage: 1.0000
- Evidence count: 8
- Normalized retrieval query: How does Rhodiola rosea extract exert senolytic activity through paraptosis?

### GPT answer

Short version
Rhodiola rosea extract appears to kill senescent cells by triggering a caspase‑independent, paraptosis‑like program: it provokes ER/mitochondrial stress and MAPK signaling that produce massive cytoplasmic vacuolization, loss of organelle function and cell collapse rather than classical apoptosis. Senescent cells are more vulnerable to this pathway because they carry high proteotoxic/oxidative and ER stress burdens and are resistant to apoptosis, so an insult that overwhelms organelle proteostasis selectively induces paraptotic death (senolysis).

Mechanistic outline
- Active constituents in R. rosea (e.g., salidroside/rosavins) can perturb cellular redox and protein‑folding homeostasis and/or interfere with mitochondrial function when given at cytotoxic doses.  
- Those insults amplify ER stress and the unfolded protein response (UPR) and increase mitochondrial dysfunction/ROS; proteostasis overload leads to progressive dilation/swelling of ER and mitochondria and formation of large cytoplasmic vacuoles.  
- Paraptosis is driven downstream by MAPK/ERK (and sometimes JNK/p38) signaling and requires de novo protein synthesis; it proceeds without caspase activation, DNA laddering, or apoptotic blebbing.  
- Because senescent cells have chronically elevated ER/oxidative stress, impaired autophagy/lysosomal clearance and an anti‑apoptotic phenotype, they are less able to buffer the additional proteotoxic/mitochondrial insult and so undergo paraptotic collapse while normal cells survive.  
- The result is selective removal of senescent cells (senolysis) by caspase‑independent paraptosis: organelle swelling → vacuolization → loss of membrane/energetic integrity → cell death.

Caveats
- The precise molecular targets in R. rosea responsible for this effect and the detailed signaling sequence are not fully established; mechanistic details come from a combination of cell biology hallmarks (vacuolization, caspase independence, MAPK dependence, cycloheximide sensitivity) and the known cellular stresses that R. rosea constituents can produce. If you want, I can summarize published experimental evidence or suggest experiments to test this mechanism.

### RAG answer

Rhodiola rosea (Rosea) exerts senolytic activity via EGCG-containing oligomers (EGC–EGCG and EGCG–EGCG) that exploit altered ER–mitochondrial calcium handling in senescent cells to trigger paraptosis-like, non‑apoptotic cell death characterized by extensive cytoplasmic vacuolization. [PMC13101718:abstract:chunk0] [PMC13101718:sec4:chunk0]
Mechanistic chain: the active constituents identified in Rosea are EGCG oligomers (EGC–EGCG and EGCG–EGCG), which are more potent than the EGCG monomer at killing senescent HUVECs and preadipocytes (oligomers act at lower concentrations) [PMC13101718:sec4:chunk0]. These oligomers target vulnerabilities in calcium dynamics between the endoplasmic reticulum and mitochondria in senescent cells, provoking time‑dependent cytoplasmic vacuolization and ultrastructural changes consistent with paraptosis rather than caspase‑dependent apoptosis (pan‑caspase inhibitor Z‑VAD‑FMK did not block oligomer‑induced cell death) [PMC13101718:abstract:chunk0] [PMC13101718:sec4:chunk0].
Phenotypic and in vivo relevance: Rosea selectively reduced viability of senescent fibroblasts in vitro and decreased reporter and tissue markers of senescent cell burden in multiple in vivo models (irradiation‑induced senescence and age/obesity‑associated accumulation), with accompanying improvements in metabolic, physical, skin, and behavioral readouts [PMC13101718:sec1:chunk1] [PMC13101718:abstract:chunk0].
Important caveats: the authors note that paraptosis lacks universally accepted molecular biomarkers, so the mode of death is described as “paraptosis‑like” and cannot be conclusively established here; the in vivo senolytic effects were demonstrated for whole Rosea but not for the isolated EGCG oligomers, and all in vivo work was done in male mice, so translational gaps remain [PMC13101718:sec6:chunk0].

---

## Q49: How are paraptosis-related genes used to build prognostic biomarkers in lung adenocarcinoma?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Emerging applications and cancer subtypes
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9421
- Top5 avg score: 0.7731
- Coverage: 0.8750
- Evidence count: 8
- Normalized retrieval query: How are paraptosis-related genes used to build prognostic biomarkers in lung adenocarcinoma?

### GPT answer

Short answer: researchers build prognostic biomarkers from paraptosis-related genes by (1) selecting genes linked to the paraptotic cell‑death pathway, (2) measuring their expression in lung adenocarcinoma cohorts, (3) statistically selecting those whose expression correlates with outcome and combining them into a multigene risk score, and (4) validating that score predicts survival and therapy response independently of clinical factors. The signature is then biologically and experimentally cross‑checked for links to paraptosis mechanisms and tumor behavior.

Mechanistic workflow (concise):
- Define a paraptosis gene set: compile genes functionally implicated in paraptosis (ER/mitochondrial swelling, proteostasis/ER stress, MAPK signaling, regulators of vacuolization).
- Measure expression and clinical data: use transcriptome datasets (tumor and, where available, normal tissue) with survival/clinical annotation.
- Discover prognostic genes: perform differential expression and univariate survival analyses (e.g., Cox) to find paraptosis genes whose expression associates with overall or disease‑free survival.
- Build a multigene model: apply regularized regression (commonly LASSO Cox) or stepwise multivariate Cox to select a minimal prognostic panel and estimate coefficients.
- Compute risk score: sum(expression_i × coefficient_i) for each patient to generate a continuous risk score; dichotomize (median or optimized cutpoint) into high‑ vs low‑risk groups.
- Validate prognostic performance: Kaplan–Meier survival curves, hazard ratios from multivariate Cox (to check independence from stage/age), time‑dependent ROC/AUC, and validation in independent cohorts.
- Biological/functional annotation: pathway enrichment, correlation with immune infiltration, and drug‑sensitivity prediction to tie the signature to paraptosis biology and therapeutic vulnerabilities.
- Experimental confirmation: assess selected genes by qPCR/IHC in tissues and test whether modulating them (knockdown/overexpression) alters paraptotic features (cytoplasmic vacuolization, ER/mitochondrial changes) and tumor phenotypes in vitro/in vivo.

Clinical use and caveats:
- The resulting biomarker can stratify patients for prognosis and suggest patients more likely to benefit from therapies that induce non‑apoptotic death or sensitize tumors to ER/mitochondrial stress.
- Limitations include cohort bias, technical/platform variability, and the need for prospective clinical validation and mechanistic proof that the genes actually mediate paraptosis in lung adenocarcinoma.

If you want, I can outline a concrete statistical pipeline (code/steps) or list typical assays to validate paraptosis experimentally.

### RAG answer

They built a prognostic biomarker by (1) identifying paraptosis-related genes (PRGs) that are differentially expressed in LUAD, (2) selecting those with survival associations by Cox regression and LASSO, and (3) combining the selected genes into a weighted risk score that stratifies patients and was validated against independent data and clinical variables. The study describes intersecting tumor vs. control differentially expressed genes with a PRG list to generate candidate genes, applying univariate Cox and PH testing, and using LASSO for feature selection to produce a risk score of the form risk_score = Σ(βgene × expression) [PMC12928938:abstract:chunk0; PMC12928938:sec4:chunk0].
The finalized signature comprised four genes (CDKN3, PEBP1, TNFRSF19, PHB); the model predicted prognosis in both training and validation cohorts and the risk score behaved as an independent prognostic factor used to build a nomogram [PMC12928938:abstract:chunk0; PMC12928938:sec23:chunk0]. The authors also report that risk scores correlated with clinical features (age, TNM stage, T- and N-stage) and that model AUCs exceeded 0.6, indicating modest predictive performance (not yet ≥0.7) and motivating further refinement [PMC12928938:abstract:chunk0; PMC12928938:sec22:chunk3].
To link the signature to biology and therapeutics, they performed functional and tumor‑immune infiltration analyses across high/low risk groups, predicted drug–gene associations via CellMiner, and validated top drug–gene interactions by molecular docking using protein structures from PDB and ligand data from PubChem [PMC12928938:abstract:chunk0; PMC12928938:sec11:chunk0]. Expression of the prognostic genes was preliminarily confirmed by RT‑qPCR on clinical LUAD samples (n=5 pairs) [PMC12928938:sec12:chunk0]. An independent study using a similar pipeline (differential expression → Cox/clustering → machine learning risk score) also highlighted CDKN3 and PHB among prominent PRGs in LUAD, supporting convergence on overlapping hub genes [paper_5225a819479c8145:abstract:chunk0].
Limitations reported by the authors include limited RT‑qPCR sample size and only moderate AUCs, indicating that while PRG‑based signatures can stratify LUAD prognosis and suggest therapeutic leads, further validation and model refinement are required before clinical application [PMC12928938:sec22:chunk3].

---

## Q50: How do paraptosis-related subtypes shape the tumor microenvironment in renal cell carcinoma?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Emerging applications and cancer subtypes
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9498
- Top5 avg score: 0.7667
- Coverage: 0.8750
- Evidence count: 8
- Normalized retrieval query: How do paraptosis-related subtypes shape the tumor microenvironment in renal cell carcinoma?

### GPT answer

Short answer: Paraptosis-related molecular subtypes likely shape the renal cell carcinoma (RCC) tumor microenvironment (TME) by altering cell death–associated signals, cytokine/chemokine profiles, metabolic state and stromal interactions, which together modulate immune infiltration, angiogenesis and immune suppression — thereby influencing prognosis and therapy response. Exact subtype–TME maps in RCC are still being defined.

Mechanisms (how paraptosis-linked programs change the TME)
- DAMPs and innate immune recruitment: Paraptotic cells undergo extensive ER/mitochondrial swelling and membrane stress that can release damage‑associated molecular patterns (e.g., ATP, HMGB1, phosphorylated proteins). These DAMPs attract and activate innate cells (dendritic cells, macrophages, neutrophils) and shape subsequent adaptive responses.
- Cytokine/chemokine milieu: Differential expression of paraptosis‑associated genes modulates production of pro‑inflammatory or immunosuppressive cytokines and chemokines (e.g., IL‑6, CCL2), changing recruitment and polarization of T cells and macrophages (M1 vs M2).
- Antigen presentation and T‑cell priming: Enhanced DAMP release and stress responses can increase dendritic cell maturation and antigen cross‑presentation, increasing CD8+ T cell infiltration in more immunogenic subtypes; conversely, some subtypes may favor tolerogenic antigen presentation and Treg recruitment.
- Immune checkpoint regulation: Paraptosis‑linked signaling (stress pathways, MAPK/ER stress) can upregulate PD‑L1 and other inhibitory molecules on tumor and myeloid cells, creating immunosuppressive niches in certain subtypes.
- Stromal remodeling and angiogenesis: Paraptosis‑associated secretome can alter fibroblast activation, extracellular matrix deposition and expression of pro‑angiogenic factors (VEGF), affecting vessel density, hypoxia and immune cell access.
- Metabolic reprogramming and hypoxia: ER/mitochondrial dysfunction tied to paraptosis changes nutrient use and ROS production; metabolic constraints or hypoxia in some subtypes favor suppressive myeloid cells and impair effector T cell function.
- Spatial heterogeneity: Different paraptosis-related subtypes can produce focal pockets of inflammation versus immunosuppression within the same tumor, leading to mixed “hot” and “cold” regions.

Consequences for prognosis and therapy
- Subtypes that elicit robust immunogenic DAMP signaling and pro‑inflammatory chemokines tend to have higher cytotoxic T‑cell infiltration and may respond better to immune checkpoint inhibitors.
- Subtypes that drive immunosuppressive cytokines, M2 macrophages, high PD‑L1 or dense stroma are linked to immune evasion, worse prognosis, and resistance to immunotherapy.
- Targeting paraptosis pathways (modulating ER stress, proteostasis or DAMP release) could reprogram the TME to improve immunotherapy efficacy, but this is an active area of research.

Caveat: Direct, subtype‑specific TME characterizations in RCC are still emerging; the above are mechanistic principles inferred from paraptosis biology and tumor immunology rather than definitive subtype maps.

### RAG answer

Paraptosis-related molecular subtypes in RCC are associated with distinct tumor‑microenvironment (TME) configurations: one subtype is immune-/stroma‑enriched with better prognosis, whereas the other shows an immunosuppressive, pro‑tumor TME with higher cancer‑stemness and mutation burden. [PMC12939344:sec19:chunk0] [PMC12939344:abstract:chunk0]
Mechanistic summary (trigger → pathway → phenotype → implication):
- Trigger/pathway: RCC tumors stratified by paraptosis‑related gene (PaRG) expression form two consensus clusters; pathway differences were assessed by GSVA and immune infiltration by ssGSEA to define functional/TME differences between these subtypes. [PMC12939344:sec3:chunk0] [PMC12939344:sec0:chunk1]
- Phenotype: the “low‑risk”/immune‑rich group has higher Stromal, Immune and ESTIMATE scores (greater immune and stromal infiltration), while the “high‑risk” group displays increased cancer stem cell (CSC) indices and higher tumor mutation burden (TMB). [PMC12939344:abstract:chunk0]
- Immune composition detail: the PaRG‑linked risk score is negatively correlated with anti‑tumor M1 macrophages and positively correlated with pro‑tumor immune subsets such as M2 tumor‑associated macrophages (which are linked to worse prognosis and promote invasion/EMT via factors like CXCL13 in RCC). Thus, the high‑risk/paraptosis‑associated subtype reflects an M2‑polarized, immunosuppressive microenvironment. [PMC12939344:sec19:chunk2]
- Genomic context: PaRGs show expression changes and CNV/mutation alterations in RCC, consistent with underlying genomic variation contributing to these subtype differences. [PMC12939344:sec12:chunk0]
Implication: paraptosis‑defined subtyping captures prognostically and biologically relevant TME states (immune/stromal abundance, macrophage polarization, CSC content, TMB) and therefore could inform personalized risk stratification and therapeutic decision‑making in RCC. [PMC12939344:sec20:chunk0] [PMC12939344:sec0:chunk0]
If you want, I can extract the specific immune‑cell differences and the four‑gene prognostic signature used to define the risk groups.

---

## Q51: How is a paraptosis-related risk signature used for prognosis and immunotherapy assessment in gastric cancer?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Emerging applications and cancer subtypes
- Retrieval strength: HIGH
- Evidence diversity: LOW
- Top1 score: 0.9599
- Top5 avg score: 0.7713
- Coverage: 0.9000
- Evidence count: 8
- Normalized retrieval query: How is a paraptosis-related risk signature used for prognosis and immunotherapy assessment in gastric cancer?

### GPT answer

Short answer
A paraptosis-related risk signature is a multi-gene expression score derived from genes linked to paraptosis (a regulated, non‑apoptotic cell death characterized by cytoplasmic vacuolization and ER/mitochondrial stress). In gastric cancer it is used to stratify patients by prognosis and to predict likely benefit from immune‑checkpoint blockade by correlating the signature with survival, tumor immune microenvironment, and known biomarkers of immunotherapy response.

How it is created and applied (mechanistic steps)
1. Gene selection: identify genes mechanistically tied to paraptosis (ER stress, MAPK signaling, mitochondrial dysfunction, regulators discovered in preclinical studies).
2. Model building: use tumor transcriptomes to select prognostic paraptosis‑related genes (univariate Cox, LASSO or stepwise regression) and derive a weighted risk score formula (sum of expression × coefficients).
3. Patient stratification: compute each patient’s score and divide cohorts into low‑ and high‑risk groups (median or optimal cutpoint).
4. Prognostic assessment: compare overall and progression‑free survival (Kaplan‑Meier, multivariable Cox) and evaluate discrimination (AUC, C‑index). A valid signature is an independent prognostic factor after adjusting for stage, age, etc.
5. Immunotherapy assessment: correlate the risk groups with features that predict immunotherapy response:
   - Immune cell infiltration (CD8+ T cells, macrophage subtypes) by deconvolution of bulk RNAseq;
   - Expression of immune checkpoints (PD‑1, PD‑L1, CTLA‑4) and chemokines/antigen‑presentation genes;
   - Tumor mutation burden (TMB), microsatellite instability (MSI) status, neoantigen load where available;
   - Computational predictors of ICI response (e.g., IPS, TIDE) and predicted drug sensitivity.
   Typically, one group (e.g., low‑risk) shows higher cytotoxic T‑cell infiltration, higher checkpoint expression, higher TMB/MSI and thus a greater predicted benefit from ICIs, while the other shows immunosuppressive TME and worse survival.

Mechanistic rationale linking paraptosis signature to immune response
- Paraptosis involves ER/mitochondrial stress and release/exposure of damage‑associated molecular patterns (DAMPs) that can modulate antigen presentation and innate immune activation.
- Tumors with high paraptosis pathway activity may therefore differ in immunogenicity, chemokine expression and immune cell recruitment, which alters sensitivity to immune checkpoint blockade.

Typical outputs and clinical uses
- Risk score for individual patients to refine prognosis beyond TNM staging.
- Predictive enrichment: identify patients more likely to respond to immunotherapy or to benefit from combination strategies (e.g., ER‑stress modulators + ICI).
- Guide experimental therapies targeting paraptosis pathways or combination regimens.

Limitations and current caveats
- Most signatures are retrospective and need prospective clinical validation.
- Performance depends on cohort, platform, and thresholds; heterogeneity across tumors can limit generalizability.
- Correlative associations (immune cell estimates, checkpoint expression) do not prove causality; functional validation is required before changing treatment.

If you want, I can outline a simple pipeline (code/algorithms and statistical tests) to build and validate such a signature using your dataset.

### RAG answer

The paraptosis-related risk signature (PRRS) is an expression-based score built from paraptosis-associated genes (notably SLCO2A1, VCAN, RAMP1 and MANEAL) that stratifies gastric cancer (GC) patients into high- and low-risk groups for prognosis and therapy assessment. The signature was derived using TCGA‑STAD as a training set and validated in GSE84433 [PMC12170466:abstract:chunk0; PMC12170466:sec16:chunk1].
Clinically, PRRS is an independent predictor of overall survival in multivariable Cox analysis and was integrated into a nomogram with TNM stage, age and sex; ROC AUCs were 0.71, 0.74 and 0.78 for 1, 3 and 5‑year survival respectively, supporting its prognostic utility across cohorts [PMC12170466:sec13:chunk0]. The authors conclude the PRRS reliably predicts survival, immune infiltration and drug response in GC [PMC12170466:sec18:chunk0].
Mechanistically/phenotypically, PRRS maps onto distinct tumor immune microenvironments: higher risk correlates positively with naive B cells, resting CD4+ memory T cells, M2 macrophages and resting mast cells, and negatively with activated CD4+ memory T cells, T follicular helper cells, resting NK cells and M0 macrophages—patterns consistent with one paraptosis-defined subgroup (C3) that had better survival [PMC12170466:sec14:chunk0; PMC12170466:sec16:chunk3; PMC12170466:sec9:chunk0]. PRRS also stratified predicted drug sensitivities: the low‑risk group showed greater sensitivity to a panel of 13 compounds (including higher predicted sensitivity to cisplatin), whereas the high‑risk group was more sensitive to afatinib, methotrexate and RDEA119, indicating possible avenues for personalized therapy [PMC12170466:sec14:chunk0; PMC12170466:sec16:chunk3]. Protein‑level IHC supported differential expression of paraptosis‑related prognostic genes (notably VCAN) between normal and tumor tissues [PMC12170466:sec16:chunk3].
Important caveat: these results are based on retrospective, public‑database bioinformatics analyses and require experimental validation (e.g., PCR, western blot, functional assays) and prospective cohort confirmation before clinical application [PMC12170466:sec17:chunk0].

---

## Q52: What common themes appear across paraptosis-related prognostic signatures in breast, gastric, lung, and renal cancers?

- Expected group: HIGH (recent 2024-2026 corpus-specific questions) / Emerging applications and cancer subtypes
- Retrieval strength: MEDIUM
- Evidence diversity: MEDIUM
- Top1 score: 0.7953
- Top5 avg score: 0.7053
- Coverage: 0.6667
- Evidence count: 8
- Normalized retrieval query: What common themes appear across paraptosis-related prognostic signatures in breast, gastric, lung, and renal cancers?

### GPT answer

Short answer: across breast, gastric, lung and renal cancer prognostic signatures that are built around “paraptosis” you repeatedly see the same pathway-level themes rather than identical genes: disrupted proteostasis/ER stress and unfolded‑protein response (UPR); mitochondrial dysfunction and reactive oxygen species (ROS) handling; MAPK/JNK and related stress‑kinase signaling that drives cytoplasmic vacuolization; calcium and ion‑homeostasis regulators; regulators of protein synthesis and the ubiquitin–proteasome/autophagy balance; links to proliferation/metabolic reprogramming; and alterations in inflammation/immune‑microenvironment signals. These shared mechanistic themes underlie both the biology that produces paraptotic morphology and the prognostic associations (including treatment‑sensitivity patterns), although the exact genes in each tumor signature differ by cancer type and context.

Caveat: the details and relative importance of each theme vary between tumor types and individual signatures.

### RAG answer

Common themes across reported paraptosis‑related prognostic signatures are: (1) paraptosis gene dysregulation defines molecular subtypes with distinct survival; (2) enrichment for extracellular matrix / cell‑adhesion and inflammation/immune pathways (and in some cases PI3K–Akt signaling); and (3) strong links between the paraptosis signature and the tumor microenvironment (immune/stromal infiltration), cancer stemness indices and tumor mutation burden—features that underpin prognostic stratification and potential therapy stratification [PMC12170466:sec9:chunk0; PMC12170466:sec10:chunk0; PMC12939344:abstract:chunk0; PMC12939344:sec14:chunk0; PMC12939344:sec19:chunk0].
Mechanistic flow: altered expression or genetic variation of paraptosis‑related genes (trigger) associates with differential activation of ECM‑related programs and signaling pathways such as PI3K–Akt (pathway), which manifests as tumor subtypes differing in cell adhesion/migration, immune effector processes and stromal composition (phenotype). Those phenotypes translate into prognostic differences (high‑ vs low‑risk groups) and correlate with immune/stromal/ESTIMATE scores, cancer stem cell indices and TMB (implication) — signatures built by LASSO/Cox (e.g., a 4‑gene RCC model and a multi‑gene GC PRRS) therefore stratify survival and suggest immunotherapy/drug‑sensitivity differences [PMC12939344:abstract:chunk0; PMC12170466:abstract:chunk0; PMC12170466:sec10:chunk0; PMC12939344:sec14:chunk0].
Data coverage limitation: the retrieved material documents these themes for renal cell carcinoma and gastric cancer and provides only a general rationale for lung adenocarcinoma biomarker work [PMC12939344:sec0:chunk1; PMC12939344:sec19:chunk0; PMC12170466:sec9:chunk0; PMC12170466:abstract:chunk0; PMC12928938:sec0:chunk0]. Evidence for breast cancer (and detailed paraptosis signatures in lung) is not present in the supplied nodes — evidence insufficient.

---

